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Optical molecular imaging has burgeoned into a major field within biomedicine, and 
technologies that incorporate surface plasmon resonance effects have become a major focus 
within this field.  Plasmon resonance has been defined as the collective oscillation of the 
conduction band electrons in certain metals (such as gold) in response to an electric field, such as 
an impinging wave of light.  We show that elastic light scattering due to the plasmon resonance of 
nanometer-sized gold particles makes them powerful tools for optical imaging of epidermal 
growth factor receptor (EGFR) expression – a major biomarker for carcinogenesis.  Optical 
technologies in general are poised as cheap, flexible ways to aid in diagnosis and treatment of 
disease.  In addition to supplying a bright, stable optical scattering signal and a convenient 
conjugation platform for targeting molecules, these materials display a unique behavior termed 
“plasmon coupling”. This term refers to the dramatic optical property changes brought about by 
the presence of other nearby nanoparticles.  These changes include a dramatic red-shifting in their 
peak plasmon resonance wavelength, as well as a non-linear, per-particle increase in the overall 
scattered power.  We show that such conditions exist in cells and are primarily due to intricate 
protein trafficking mechanisms as part of the EGFR life-cycle. The observed variations in 
 vii 
plasmon coupling can give clues as to the nanoscale organization of these important proteins.  In 
addition, the resulting optical property changes result in a large, molecular-specific contrast 
enhancement due to the shifting of the resonance closer to the near infrared region, where 
biological tissues tend to be most transparent.  Despite this enhancement, however, many tissues 
contain large endogenous signals, as well as barriers to delivery of both light and the 
nanoparticles.  As such, we also show an example of a multifaceted approach for further 
increasing the apparent molecular-specific optical signals in imaging of EGFR expression by 
using an oscillating magnetic field.  This serves to encode the signal from magnetically 
susceptible plasmonic nanoparticles, making their extraction from the background possible.  
Overall, the studies presented in this dissertation should serve to stimulate further investigations 
into a wide variety of technologies, techniques, and applications.   
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1.1 THE AGE OF MOLECULAR MEDICINE 
Historically, the method by which most physicians detected and treated disease was 
based on macroscopic observables of the patient’s condition and his/her response to 
therapy.  With the advent of microscopic techniques in medicine by Malpighi [2], Hooke 
[3], and Leeuwenhoek [4], the gradual adoption of adjuvant imaging systems in medical 
practice progressed.  Through succeeding decades, the use of microscopy in medicine 
required resection of tissue from a patient for staining and examination in a compound-
type microscope, and this is still standard practice for many diseases that must be 




 centuries, however, 
technologies such as X-ray imaging, computed tomography (CT), Ultrasound, positron 
emission tomography (PET) and magnetic resonance imaging (MRI) vastly expanded the 
repertoire of imaging methods used in medical practice, and allowed for an in-vivo 
evaluation of the patient, often with relatively good spatial and/or temporal resolutions 
[6] that allow for high confidence in predicting disease.  Yet, the majority of information 
typically gleaned from current modalities (with notable exceptions such as fMRI and 
PET) remains anatomical. That is, the images are of tissue micro-structure and 
architecture, and do not necessarily contain detailed information about the genetic or 
proteomic makeup of the tissue.  While structural information can be very useful, it may 
not directly relate to that tissue’s function.  Or, in the case of a pathophysiological 
condition, the anatomic manifestation of a functional abnormality may not appear until 
successful treatment has become considerably less likely.  This is particularly true in the 
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case of cancerous or neoplastic lesions, where molecular changes usually precede 
anatomic abnormalities [7].  Because of this, the early detection and treatment of 
carcinogenesis remains an excellent strategy for prolonged survival. 
Concomitantly with advances in in-vivo medical imaging techniques, molecular 
biological investigations throughout the latter half of the 20
th
 century began to shed light 
onto the underlying molecular mechanisms responsible for many pathogenesis processes, 
particularly carcinogenesis [7].  Indeed, entire metabolic, catabolic, and signaling 
cascades have been elucidated with the aid of bioanalytical methods.  This has led to a 
molecular characterization of many cancerous diseases and has resulted in a greater 
understanding of their molecular underpinnings and the resulting anatomical 
abnormalities normally observed by a physician or pathologist.  Although the fields of 
medical imaging and molecular biology have made great strides in the last 50 years, the 
synthesis of these two disciplines is still in its infancy.  However, the promises of success 
are attractive so say the least.  Currently, there is, to a large degree, a disconnect 
remaining between minimally invasive imaging and molecular characterization of cancer.  
On the one hand, the presence of a myriad of biological markers can be ascertained from 
a patient, but only after removal of the diseased tissue and subsequent staining and 
microscopic examination [5].  This presents two problems: the removal of diseased tissue 
requires an invasive procedure, whose risks may not be negligible, depending on the 
organ site [8].  Second, the removal of a neoplastic growth implies that it can be detected, 
usually nested among normal tissue – a fact that may indicate that the disease has already 
progressed to a dangerously advanced state.  Alternatively, the taking of biopsies before 
disease is visually apparent becomes a random point-sampling procedure that only has a 
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certain statistical chance of detecting cancer.  On the other hand, conventional medical 
imaging can allow for rapid screening of a patient over a relatively large tissue volume.  
However, the molecular information currently available from such modalities is still 
rather limited, although emerging technology has begun to allow some molecular 
imaging in MRI [9-11], PET/CT [12-15], and ultrasound [16-20].    A persistent problem 
still exists, in that all of these techniques also have relatively limited spatial resolution 
[6], typically not sufficient to resolve very small lesions at a point where they are the 
most curable.  As such, new paradigms may be needed to fully integrate the vast network 
of knowledge built up from the last 50 years of molecular biological investigation with 
the promising technical advances utilized in biomedical imaging. 
1.2 NANOTECHNOLOGY AND BIOMEDICAL APPLICATIONS 
In 1960, the celebrated physicist Richard P. Feynman was quoted as saying, “The 
problems of chemistry and biology can be greatly helped if our ability to see what we are 
doing, and to do things on an atomic level, is ultimately developed – a development 
which I think cannot be avoided.”  These sentiments underscored widely attended 
lectures by Feynman, entitled “There’s Plenty of Room at the Bottom”, in which he 
implored for the need to develop systems, techniques, or platforms that can interact on 
atomic/molecular level – i.e. the nanoscale [21].  Feynman seemed to sense the need for 
materials that could sense and report events happening far below the limits of human 
perception.  Interrogation of endogenous sources of signal (whether it be via photonic 
excitation or otherwise) has great value, although it retains some limitations.  Generally, 
the optical signature of most biomolecules is not specific enough to identify particular 
species, or, though specific, exists within the tissue milieu such that positive 
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identification remains difficult.   A better overall strategy might be to access and 
intervene in the molecular world of living cells and their machinery using similarly-sized 
externally introduced materials.  This scheme may be preferable whether the purpose is to 
merely “report” the presence or location of a particular molecular, or to “intervene” – i.e. 
to therapeutically change a particular process within the cell.  While the exact size range 
of what constitutes the “nanoscale” is not clearly defined, perhaps a relatively forgiving 
range would be from 1-1000nm.  A stricter definition might only include structures 10-
100nm, historically named the mesoscale – literally, length scales  in the middle – 
describing size ranges that are not always representative of the bulk material, but cannot 
be treated as single atoms either.  This is the length range where quantum physics starts 
to become bulky, while classical physics cannot always be applicable.  Materials of this 
length scale encompass a large range of technologies, whose application may be 
diagnostic, therapeutic, or both.  Table 1.1, adapted from [21] , attempts to collect some 
examples of nanotechnology currently under development for biomedical applications, 
and represents a selected sampling of some of the more popular directions. Clearly, the 
overall field of bionanotechnology is growing rapidly, and the purview of applications is 
broadening at an equal rate. This ranges from experimental diagnostics, in the case of 
quantum dots [22-24], to therapeutic carriers [25-28], to therapeutic agents [29] to 
multifunctional agents that can both sense and treat, [30-35].  As stated above, 
nanomaterials are advantageous due to the comparable size scale as the biomolecules 
they interact with.  In addition, a good nanotechnology platform should retain a large 
amount of flexibility in terms of its application, as well as be mass producible.  At the 
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current stage, no single technology represents a panacea for cancer diagnostics or 
treatment. 
Table 1.1.  Selected Examples of nanotechnology in biomedical applications 
 
1.3 OPTICAL TECHNOLOGY, NANOPARTICLES AND MEDICAL IMAGING 
As shown in Table 1.1, there are a multitude of nano-scale technologies currently 
under development for biological/medical application.  Of note is the fact that many of 
these technologies rely on an optical component for activation or interrogation.  Quantum 
dots, nanoshells, nanorods, nanodiamond, carbon nanotubes, as well as porous silica are 
all optically active, reflecting the fact that optical-based technologies have become 
popular as possible cancer diagnostic aids and interventions.  The reasons for this are 
multitude, and will be dealt with in more depth later.  Briefly, however, optical methods 
are relatively cheap, as compared to MRI, CT, or even ultrasound [51].  Secondly, the 
practically achieved resolution limit of optical technologies is in the hundreds of 
nanometers to micron range.  MRI, CT and ultrasound all fall within the hundreds of 
microns to millimeter range in medical practice [6].  The resolution improvement 
Technology Typical Size Application(s) 
Quantum Dots 1-10nm Fluorescence-based molecular 
imaging, both in-vitro and in-
vivo [22-24] 
Plasmonic Nanoparticles 15-200nm Reflectance-based molecular 
imaging, photothermal ablation 
of cells [30-35] 
Magnetic Iron Oxide 
Nanoparticles (SPIO) 
5-10nm MRI contrast agents, often used 
to image blood flow and 
atherosclerotic plaques [36-42] 
Nanodiamond 60-100nm NIR fluorescence from NV
-
 
defects, for use in fluorescence 
imaging [43-45] 
Fullerene (C60) 2-20nm Antioxidant [29] 
Carbon nanotubes 1-100nm diam., 20-1000nm 
long 
Fluorescent sensor [46-48], NIR 
Photoablation [49, 50] 
Porous Silica 10-1000nm Drug delivery [25-28] 
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available with optical technology makes identifying small lesions much easier, providing 
an inexpensive way to effectively screen, intervene, and monitor treatment.  Optical 
techniques may also be used to provide visual cues during surgery, particularly via 
functional molecular imaging.   
The ability to accurately visualize the three-dimensional tissue architecture is 
absolutely critical.  MRI, CT, and ultrasound all have the ability to represent the imaging 
volume in a 3D manner.  Optical imaging, too, can achieve this through the 
implementation of some type of “gating” or “sectioning” mechanism that rejects out-of-
focus light.  This is a relatively new development in optical imaging, one that recognizes 
the need to move beyond 2D imaging available with traditional optical microscopes.  To 
date, there are two popular strategies for achieving this “gating” principle, while 
maintaining high resolution.  The first to be developed physically blocks the out-of-focus 
light from entering the detection path of the microscope by placing an aperture at the 
conjugate image plane on the far side of the microscope’s object lens.  This is the so-
called confocal principle that was proposed by Minsky in the 1950s [52].  The second 
main sectioning strategy is via the use of coherence gating, which spawned the invention 
of optical coherence tomography (OCT).  This setup uses an interferometer to induce 
constructive interference at the conjugate image plane, thereby creating an optical 
sectioning effect this way [53].  In either case, the depth at which optical or near infrared 
photons can penetrate human tissues does not generally exceed the millimeter range [54]. 
It is important to note that there are also diffuse optical tomographic imaging techniques 
that are able to resolve optical signals in three-dimensions.  However, resolution using 
these techniques is much larger that either confocal or OCT microscopies [55].   
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From this initial discussion, it can be seen that the combination of optical and 
nanoscale technologies may prove to be a powerful approach to solving certain 
biomedical problems, particularly detection of tumorigenesis that occurs in superficial 
tissues.  Of the technologies listed in Table 1.1, the current two most popular strategies 
(as evidenced by number of publications) are molecular-specific fluorescence imaging 
using semiconductor quantum dots (qdots) and imaging using scattering/absorption from 
plasmonic nanoparticles (which include nanoshells, nanorods, spherical nanoparticles and 
all variations within).  Both of these technologies have complementary features, and the 
best particular solution may remain application-dependent.  On the one hand, quantum 
dots, in general, have a narrower emission profile, as compared to the plasmon resonance 
of gold nanoparticles, which makes them arguably more suitable for multiplexing 
applications  by altering size and composition [24, 56-59].  However, they are also 
comprised of highly toxic components [60-62], and do suffer from photobleaching (albeit 
at a much lower rate than traditional fluorescent dyes) [23].  Plasmonic nanoparticles are 
also spectrally tunable (that is, their peak plasmon wavelength can be altered by changing 
the constituent material and geometry), but their plasmon resonance peak is usually wider 
than the emission peak of qdots [30, 63].  Plasmonic particles are, however, comprised of 
less toxic noble metals (gold and silver), with or without combinations of a dielectric 
material [30, 64].  Gold-based nanoparticles, in particular, have been shown to be non-
cytotoxic, even at high dosage [65], and have been used as therapeutic carriers in one 
study with human subjects, with no reports of adverse effects due to the gold [66].  In 
addition, gold/silver nanoparticles have a greatly simplified conjugation strategy 
associated with them, as organo-gold interfacing chemistries are quite well characterized 
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via years of use as electron microscopy stains [67, 68], although conjugation strategies 
for qdots are also widely available [24, 59, 69].  Plasmonic particles, however, have 
higher optical cross-sections than qdots [70], do not photobleach [63], and display a very 
interesting phenomenon of “plasmon coupling”, whereby their optical properties shift in 
response to the presence of other resonant scatterers in the near field [71-74].  This 
phenomenon does not have a clear analog in other modalities, although the FRET concept 
is somewhat similar in application [75], with several important drawbacks.   
As will be explained further, plasmon coupling acts as a means by which molecular 
trafficking and interactions can be monitored, as well as a mechanism by which greatly 
increased optical signal and contrast is possible.  It is this phenomenon which will act as 
the undercurrent for most of the work contained in this dissertation.  The other unifying 
concept will be the use of epidermal growth factor receptor (EGFR) as a biomarker for 
carcinogenesis.  As will be discussed further, this is a well characterized membrane-
bound receptor [76], and has been the object of several recent molecular imaging studies 
using both plasmonic particles [77-81] and qdots [82-85]. 
1.4 OUTLINE OF SPECIFIC AIMS 
The aims of this dissertation will provide insight into molecular imaging of EGFR 
using plasmonic particles and to explore the phenomenon of plasmon coupling with the 
intension of exploiting it to gain information that may not be attainable using other 
optical/nanotechnology methods.  These studies were carried out in progressively more 
complex biological models.  In addition, further studies will be shown that point to the 
utility of using hybrid nanoparticles and a multi-faceted approach to help further improve 
molecular-specific contrast.  To that end, the four aims of this dissertation are as follows: 
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1. First, we study and characterize the phenomenon of plasmon resonance coupling 
in cell suspensions labeled with spherical gold nanoparticles targeted for EGFR 
expression.  This work establishes some basic principles needed to evaluate the 
level of contrast enhancement that is possible, and to what degree plasmon 
coupling plays a role.  It will be shown that plasmon coupling is centrally 
responsible for highly increased optical contrast when imaging epidermal growth 
factor receptor (EGFR) expression, as compared to normal or non-expressing 
samples, in the near-infrared region.  This is due to the marked red-shifting of the 
plasmon resonance upon particle binding to cells, as well as a non-linear 
relationship between particle concentration on/in the cells and the overall 
scattering signal. 
2. Second, the relationship between the plasmon coupling effect and the nanoscale 
arrangement of EGFR will be investigated.  These studies focus on the labeling 
dynamics and EGFR trafficking patterns within living cells.  It will be shown that 
gold nanoparticles are sensitive to the nanoscale arrangement of EGFR molecules 
both on the surface of the cell, as well as after endocytosis.  We will show a 
progressive red-shifting of the plasmon resonance as gold nanoparticle-labeled 
EGFR molecules collect on the cell surface and internalize into endosomal (and 
later lysosomal) compartments, consistent with currently held mechanistic 
models.  These observations are independently confirmed through electron 
microscopy and are evaluated quantitatively using hyperspectral imaging.   
3. The principles developed in aims 1 and 2 can then be used to help explain 
labeling patterns seen in more complex biological models in an effort to further 
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evaluate gold nanoparticles’ appropriateness as a means for early cancer 
detection.  Aim 3 serves to extend the applicability of immuno-targeted gold 
nanoparticles from single cell suspensions to homogeneous and heterogeneous 
three-dimensional synthetic tissue constructs to ex-vivo human cervical tissue and 
animal xenografts, as well as to an in-vivo animal model.  We will show that 
normal to abnormal signal ratio is higher than what would be expected using 
linearly behaving reporters.  That is, we show signal enhancement in a variety of 
biological models far above the factor of EGFR over-expression.  This is 
important in the case of molecules (such as EGFR) that are not necessarily 
uniquely expressed in neoplastic tissue, but experience increased expression, or 
modulate their nanoscale arrangement.  Further, we show preliminary data to 
support the use of gold nanoparticles as a means to detect micrometastases in 
sentinel lymph nodes in oral cavity carcinoma. 
4. Finally, a study is shown that indicates how hybrid plasmonic nanoparticles can 
be used to further increase optical contrast in EGFR imaging.  Through the use of 
iron oxide/gold hybrid nanoparticles in an oscillating magnetic field, the 
molecular-specific signal can be modulated with a user-defined frequency.  By 
capturing the time-varying signal, and applying simple Fourier-based filtering 
algorithms, the specific to non-specific signal ratio can be increased a further 3-4 
fold over unlabeled cells, or those labeled pure-gold particles alone.   We believe 
this study opens up further opportunities in multi-modal cellular monitoring and 
possible mechanical actuation of signaling cascades that are implicated in cancer 





2.1 MOTIVATION:  CANCER STATISTICS 
While optical molecular imaging with gold nanoparticles may be applicable in a 
number of health-related areas, the problem of cancer remains a formidable one that 
deserves application.  The myriad of disease states that fall under the general category of 
“cancer” represent a staggering worldwide cost both in terms of material resources and 
human lives.  Worldwide, more than 6 million people die from cancer each year and 
more than 10 million new cases are detected.  In most developed countries, cancer is the 
second leading cause of death, behind only cardiovascular disease [1]. As figure 2.1 
indicates, while the death rates due to many serious health threats such as heart disease, 
stroke, and respiratory infection have been dramatically reduced in the US over the past 















 Figure 2.1  Death rate changes between 1950 and 2003 for the four leading 





























The overall cancer survival rate in the US is about 65% - that is, nearly 2 in 5 cases of 
cancer are fatal [1].  It is also important to note that 85% of all malignant growths begin 
in the epithelial lining of organs such as lung, cervix, oral cavity, skin, colon, etc [86].  
This is significant, as it points out that most cancers are initially superficial diseases, and 
can often be treated successfully when identified at this early stage.  For example, the Pap 
smear for cervical cancer is considered one of the most successful implementations of 
such early screening strategies.  Between 1955 and 1992, the number of deaths from 
cervical cancer declined by 74% in the United State [87].  Conversely, lesions in the oral 
cavity typically have a lower overall survival rate, due to the lack of widespread 
screening techniques in the US, which result in the lesions generally being detected at a 
much later stage.  This leads to treatments that are more difficult, more expensive, and 
less successful.  Overall five-year-survival rates for patients with advanced stage disease 
remain at 30-40% or less [1]. 
2.2 THE MOLECULAR CHARACTERISTICS OF CANCER 
There are several widely-accepted features that most or all cancerous growths have in 
common, and have been put forth by Hanahan and Weinberg [7].  These include:  (1) the 
ability to evade apoptosis, (2) sustained angiogenesis, (3) limitless replicative potential, 
(4) ability to invade and metastasize, and (5) insensitivity to growth regulatory signals.  
There are numerous specific proteomic and genomic biomarkers for each of these 
characteristics.  For example, apoptosis is a critical process by which abnormal cell 
functioning is detected and results in programmed cell death.  Both the insulin-like 
growth factor receptor (IGFR) [88] and receptors for transforming growth factor [89] 
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proteins modulate this process, and abnormalities in either of these biomarkers can result 
in abnormal cells being allowed to continue to live and replicate.  Telomerase proteins 
are often responsible for the ability of cancer cells to replicate themselves indefinitely by 
maintaining telomere length during mitosis [90].  For a tumor to survive past the initial 
stages, it must be able to recruit blood vessels into its volume, and molecules such as 
vascular endothelial growth factor VEGF receptor can cause the growth of new 
capillaries in order to sustain the abnormal tissue [91].  Perhaps the most dangerous 
feature, metastasis, is regulated by numerous proteins, chief among them the 
metallomatrix protease (MMP) family (especially MMP-2 and -9) [92-94].  These 
enzymes catalyze the destruction of connective tissue within the epithelial stroma, 
allowing cells to enter the underlying vasculature or lymphatic tissue in order to spread to 
distant organ sites.  
Of the five aforementioned characteristics, the insensitivity to growth regulatory 
signals was the first to be identified by molecular biologists and oncologists, and hence 
has the most complete literature treatment.  This ability refers to the tendency of most 
cancer cells to either maintain a high growth rate despite low extracellular growth factor 
concentrations (through alterations in homeostasis), despite high amounts of anti-growth 
signaling molecules, or both.  There are three main compartments in which this ability 
can rise (often simultaneously).  The first is at the stage of growth factor production.  For 
most cells in the body, growth factor signals are produced by other cells – termed 
heterotypic signaling [7].  Some cancer cells, however, attain the ability to synthesize 
their own growth factors, which can produce a positive feedback loop, or “autocrine” 
pattern in the cells’ growth circuitry.  A second point of disfunction can exist at the level 
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of effector molecules inside the cell.  Disfunctions arising within the internal circuitry of 
a cell’s transcription factor regulation pathways can cause a host of abnormalities 
resulting in insensitivity to signaling cascades. The protein p16 is a classic example [95].   
The third compartment, and one of the first to be discovered, is at the growth factor 
receptor level. It is here that the growth factor signal is transduced to the effector 
molecules that initiate DNA synthesis, mitosis, and other processes.  The growth factor 
receptor stage represents a logical starting point for optical molecular imaging.  First, it is 
one of the most studied areas in molecular oncology, and thus its biology is relatively 
well-understood.  Second, its presence on the cell surface represents an ideal area to 
target:  unlike growth factors, receptor molecules are located (though often transiently) 
on the cell membrane.  As such, cells that up-regulate or disregulate these molecules are 
relatively easy to recognize in an imaging scheme.  Also, unlike the internal effector 
molecules, imaging labels need not be functionalized with additional cell membrane-
entry or disrupting factors to permit introduction into the cell. 
2.3 THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) FAMILY   
Although there is a multitude of growth factor receptors, the epidermal growth factor 
receptor (EGFR) is perhaps the most studied receptor of its type [76, 96-106].  It has been 
placed within the erbB receptor family, (and is sometimes referred to as erbB-1), whose 
family consists of at least three other similarly structured receptor tyrosine kinases 
(together often named erbB-1 through -4), with various ligand specificities.  These 
proteins are also often referred to in breast cancer contexts as belonging to the HER 
protein family (whereby each member is referred to as HER-1, HER-2, etc. [107]). For 
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the sake of clarity, EGFR will be referred to as belonging to the erbB family in this 
dissertation. 
The erbB family represents the external to internal signal transduction point for many 
cellular processes, including proliferation, survival, migration, and differentiation [108]. 
Each of the four known erbB receptors has an extra-cellular portion, a single trans-
membrane domain, and a cytoplasmic portion.  Defining characteristic of all the erbB 
proteins include dimerization-dependent activation (either homo-dimerization [109], or 
hetero-dimerization [110]), usually with a 2:2 ligand:receptor stoichiometry (with the 
notable exception of erbB-2, which has no known ligand [110]).  For a summary of the 
ligand specificities for each of the erbB receptors, refer to table 2.1, adapted from [111]. 
Table 2.1  Summary of each erbB member and known ligands, summarized from [111]. 
erbB Member Known Ligands 
erbB-1 (EGFR) Epidermal growth factor (EGF), transforming growth factor α 
(TGF-α), amphiregulin, betacellulin, heparin-binding EGF, 
epiregulin 
erbB-2 None 
erbB-3 Neuregulin 1 and 2 
erbB-4 Neuregulin 1-4, betacellulin, heparin-binding EGF, epiregulin, 
tomogregulin 
 
Ligand binding and dimerization elicits cross-phosphorylation of various tyrosine 
residues on the cytoplasmic domains of both receptors.  This allows binding of effector 
molecules including the MEK/MAPK cascade [112] , SoS [113], Ras [114], Grb2[114] 
and others [115-117], eliciting DNA transcription, and other results as described above.   
This dissertation will focus primarily on imaging of the first member of the erbB 
family – erbB-1 or EGFR.  The 175kD EGFR protein was first recognized as a possible 
receptor in fibroblast cells in 1973 by Hollenberg and Cuatrecasas [118], and later 
positively identified [119].  In subsequent studies, the structure [120], biophysical 
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properties [121, 122], as well as possible stimulating and inhibitory mechanisms [123-
126] begun to be elucidated.  Early on, it was recognized that EGFR molecules tended to 
cluster on the cell surface [127-131].  It was not until later that dimerization was found to 
be the activation “quanta” of this particular protein [132, 133], accompanied by higher-
order aggregation in clathrin-coated pits on the cell surface [134-136].  It is this 
aggregation that forms the precursor of EGFR endocytosis and internalization in response 
to ligand binding, and represents a vital regulatory mechanism of EGFR signaling [97, 
135, 137, 138].  The processing of internalized EGFR molecules is still an active area of 
research.  Many basic internalization and processing mechanisms have been elucidated 
[139, 140], although a more nuanced view of the model is currently being developed.  
The basic mechanistic view postulates that upon ligand binding, dimerization, 
aggregation in clathrin-coated pits, and internalization, EGFR receptors are trafficked 
through the endocytotic pathway via microtubule-directed motion [135, 141] and tagged 
with the sorting/degradation marker ubiquitin before destruction in lysosomes.  Of great 
interest currently is the hypothesis of EGFR “recycling” – that is, the tendency of some 
cells to reuse EGFR receptors by bypassing the lysosomal degradation pathway and up-
regulating the re-fusion of EGFR-laden vesicles back into the plasma membrane.  
Though a number of studies have detected this effect indirectly [136, 142], this behavior 
seems to have been observed only in one limited study [143] based on fluorescence 
quenching of labeled EGFR molecules upon internalization. 
2.4 OPTICAL IMAGING OF BIOLOGICAL TISSUE 
This rich, well characterized network of downstream effectors, as well as elegant and 
nuanced regulatory mechanisms makes EGFR a fertile area to begin studying using 
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plasmonic nanoparticles.  Using optical phenomena for this type of detection, however, 
begs the questions as to whether this type of technology could effectively be 
implemented in a clinical setting.  As described previously, optical technologies are most 
adept at detection of epithelial cancers – which account for approximately 85% 
neoplastic growths seen in the clinic [1].  This is due to the fact that such lesions exist 
less than 1 mm from the organ surface, which can potentially be accessed by endoscopic 
probes [144].  Optical or near-infrared wavelength illumination can easily penetrate these 
thicknesses to reveal morphologic and/or chemical change [145-148].  This is 
advantageous because optical technologies are comparatively cheaper than most other 
imaging modalities such as MRI or CT, while at the same time allowing for resolutions 
down to sub-cellular levels in-situ, without the use of ionizing radiation.  Light-based 
technologies such as optical coherence tomography (OCT) and confocal microscopy have 
shown the ability to diagnose early cancerous growths in-vivo with specificities and 
sensitivities that meet or exceed current clinical practices.  For example, Collier et al. 
were able to distinguish high-grade cervical intra-epithelial lesions (those with a high 
probability for progression) from normal and low grade cases (those with a low 
probability for progression), with a sensitivity and specificity that exceeds that of the Pap 
smear [149].  The diagnostic parameters were based on cell nuclear morphometric 
measurements such as the nuclear to cytoplasmic ratio and average nuclear area. These 
features are currently clinically measured via costly and time-consuming histological 
analysis.  This study indicated that, consistent with histological examinations, the average 
nuclear size and shape distribution increases markedly as pre-cancerous changes 
progress.  In a pilot clinical study, the diagnostic performance of this technology was 
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evaluated against a conventional histopathologic diagnosis, and produced a sensitivity of 
100% and specificity of 91% in detection of severe dysplasias.  This is encouraging, 
when compared to the current clinical paradigm of Pap smear screening and colposcopic 
diagnosis, which have substantially lower overall specificities and only comparable 
sensitivities [150].  Similarly encouraging results have been attained using optical 
coherence tomography (OCT) in a variety of organ sites [147, 151], indicating that 
statistically significant signal intensity changes can accurately predict pathological 
changes.  While the sources for these changes can be varied, in the case of epithelial 
cancers, the increase in signal seen with neoplastic changes seems to be due in large part 
to carcinogenesis-mediated increases in cell nucleus size, as well as nuclear texture and 
shape irregularities, as suggested by a number of studies [146, 152].   
While the above examples indicates the level of information attainable using 
reflectance or scattering-based modalities, fluorescence confocal imaging and 
spectroscopic techniques can also provide valuable, clinically relevant information for a 
variety of diseases, including cancer [153-158].    In contrast to reflectance-based 
techniques, which derive signal sources from refractive index mismatches  arising from 
cell nuclei and other microanatomical features [159], fluorescence based techniques 
derive their signals from specific chemical components within cells and connective 
tissues.  There have been numerous fluorophors identified that are commonly present in 
living tissues [160-162], including several flavinoids, particularly the electron carrier 
FAD
+
 [154], as well as NADH [160], porphyrins [163], as well as the formation of 
complex fiber cross-links in connective tissues, especially collagen [158].  In particular, 
the electron carriers FAD
+
 and NADH have been shown to be positively correlated with 
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dysplastic state, while collagen-based fluorescence seems to be negatively correlated with 
disease [164]. 
Despite the multitude of promising results using endogenous sources of optical 
contrast in tissues, the number of chemical species that can be potentially identified using 
either scattering or fluorescence techniques is limited.  More specificity can potentially 
be attained through the detection of endogenous Raman-type scattering from tissues [165, 
166], due to the chemical sensitivity of this method. A lack of signal strength, however, 
as well as the highly complex mixture of thousands of chemical species in typical 
biological tissue seems to hinder this approach somewhat for identification of specific 
cancer-causing proteins, and rather seem to favor utilizing net differences in overall 
signals from healthy and diseased tissue.   
2.5 MOLECULAR IMAGING:  FLUORESCENT CONTRAST AGENTS 
As an alternative to probing for endogenous sources of optical signal, another method 
may involve using externally derived optically active compounds that can be exposed to 
tissues in order to gain molecular specificity.  Such materials are often termed “contrast 
agents”.  Organic fluorescent dyes are traditional contrast enhancing molecules for in 
vitro and in vivo optical imaging [167-170], and are widely used in many 
biological/biomedical investigations to determine expression level and localization of 
biomarkers, particularly in drug development [171], albeit often using fixed samples 
(although live cell molecular imaging is becoming more widespread [172-175]).  
Fluorescent dyes have been developed that exhibit increased photostability [176], as well 
as functional sensitivity to pH [177], membrane potential [178], or a particular ion such 
as Ca
2+
 [179], among other factors. 
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  Recent advances, particularly in materials science, have also led to the development 
of semiconductor quantum dots [23, 60, 180-182].  Quantum dots have gained much 
popularity over the past 8-10 years after their initial report as effective biological imaging 
agents [23].  These 2-10nm diameter agents are comprised of semiconductor materials 
that (due to their small size) display a quantum confinement phenomenon, thereby 
creating a well-defined energy level band gap that can be exploited to produce 
luminescence with high quantum efficiency, narrow spectral bandwidth, and relatively 
increased photostability [22, 183].  Because of this, there has been widespread 
recognition that quantum dots provide a flexible platform for optical molecular imaging.  
However, there are some problematic issues with this technology.  First, although 
quantum dots are more resistant to photobleaching than organic dyes, their signal does 
still degrade somewhat over time [23].  Further, they display a so-called “blinking” effect 
– discrete “on” and “off” states that could making their use in very sensitive assays 
questionable [184].  Most troubling, however, is the fact that quantum dots are typically 
synthesized using highly toxic metal/semiconductor materials.  To date, relatively little 
work has been done in evaluating the possible biocompatibility issues surrounding this 
technology [62].   
Beyond this, there is emerging realization that simply imaging the expression and 
location of a biomarker may not provide enough information to fully impact clinical 
practice.  Functional molecular imaging is a term that could refer to the ability to image 
the presence, localization, and behavior of a proteomic biomarker on the molecular scale.  
Two main strategies have been developed, which are related, to gain this type of 
information though an optical imaging approach.  By far the most popular is the 
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fluorescence resonance energy transfer (FRET) technique [75], which utilizes a pair of 
fluorophors; one fluorophor acts as a “donor”, while the other acts as a “acceptor”.  The 
simplified mechanism is as follows:  The donor is excited at near its optimal wavelength, 
whereby its relevant electrons are excited.  If the proximity of the acceptor fluorophor is 
sufficient, a certain percentage of the energy contained in the donor’s excited state 
electrons is non-radiatively transferred to the acceptor dye.  Thus, the acceptor is 
indirectly excited, and emits luminescence only in close proximity to its donor 
fluorophor.  While this technique has proved eminently useful, there are still drawbacks.  
First, the donor and acceptor fluorophors must have overlapping absorption/emission 
spectra – representing a limited number of fluorophor pairs.  This also implies that the 
traditional FRET technique can only quantitatively detect co-localization of two 
recognizably distinct populations of molecules – and will not be easily applicable for 
situations such as EGFR homodimerization, which represents the association of two 
identical molecules. From a more technical point of view, FRET also suffers from 
relatively low energy transfer efficiencies that depend on the sixth-power of the donor-
acceptor separation distance, typically less than 10nm [185], as well as a careful 
alignment of the donor-acceptor dipoles for stable energy transfer.   
A second main strategy, although not as fully utilized as of yet, allows the probing of 
a single enzyme’s function via energy transfer – not unlike FRET – but utilizes a 
fluorescent/quencher pair of moieties that are synthesized in the “off” state – that is, the 
fluorescent moiety is in close vicinity (less than 10nm) to a quenching material (i.e. 
prevents fluorescence) through a linker that has bioreactivity to the enzyme of interest.  
So far, this concept has elicited a number of interesting techniques that attempt to 
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selectively image the enzymatic activity of proteolytic enzymes, which are a critical 
component of a cancer cell’s ability to extricate itself from its tissue of origin and to 
invade distant organ sites. Upon exposure to the enzyme, this linker is hydrolytically 
cleaved, thus releasing the fluorophor from proximity to the quencher, and allowing 
normal luminescence to occur under proper optical excitation.  Such a strategy has 
incorporated organic fluorophors as both the emitter and quencher [170, 186], as well as 
quantum dots as the emitter [187].  These technologies have proven to provide interesting 
insights into the proteolytic behavior of cells, but their application to other proteomic 
studies seems limited.  Of particular interest would be to optically image the nanoscale, 
long-term behavior of one or more of the innumerable regulatory proteins that control 
vital cell functions, and whose dysfunction can result in a diseased state.    
2.6 PLASMONIC NANOPARTICLE CONTRAST AGENTS 
2.6.1 Observations of Optical Properties 
As early as 1857, Michael Faraday recognized the unique interactions between 
nanometer sized gold particles and light [188].  These interactions revolve around the 
excitation of conduction band electrons, called the surface plasmon. Mathematically, a 
plasmon resonance corresponds to a resonant scattering phenomenon whereby the real 
part of the dielectric function of the metal is negative and its magnitude is greater than 
that of the surrounding media.  Figure 2.2 shows the total extinction spectra of 25 nm 




As can be seen, this optical behavior produces a characteristic spectral signature, 
much in the same way a particular fluorophor would.  One of the more attractive 
properties of gold nanoparticles, however, is a scattering cross-section (which is defined 
later) that greatly exceeds the analogous fluorescence cross-section of most common 
fluorescent dyes.  Moreover, since the light interaction of interest is based on elastic 
scattering, photochemical reactions do not occur.  Figure 2.3 graphically illustrates the 
relative optical cross sections of gold nanoparticles as compared to other common 
optically active materials. The scattering cross section of gold nanoparticles is 
significantly larger than the fluorescence cross section of conventional probes such as 
rhodamine-6G, FITC, a typical Alex Fluor dye, or enhanced green fluorescent protein 
(eGFP).  Indeed, one 60 nm gold particle has the same cross section as 3 x 10
5 
fluorescein 
molecules.  This allows for much more sensitive detection schemes that are also more 
stable over time.  It has been reported that gold nanoparticles can be detected down to a 





 M in bulk spectroscopic measurements [189], and single particles 














As stated before, the peak wavelength of a particle’s plasmon  resonance is a function 
of particle size, shape, material, and surrounding media [159].  The theoretical reasons 
for this will be explained later, but its implication is that plasmonic nanoparticles can 
exist in differing “colors” – that is, their maximal scattering wavelength can be adjusted 
by changing size, shape, or constituent material.  For example, figure 2.4 shows scattered 
light from a series of metal colloidal solutions of varying sizes (15-200nm) and varying 




Figure 2.3.  Relative efficiency factors of nanoparticles 
compared to fluorescent dyes [data unpublished].  
Figure 2.4.  Scattering from colliodal solutions of varying 
compositions and sizes [data unpublished]. 
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While these observations have attracted much attention, perhaps the most intriguing 
properties of plasmonic nanoparticles center around the optical property shifts seen in 
nanoparticle clusters. It has been observed that as the mean interparticle distance in a 
group of plasmonic nanoparticles decreases, the scattering efficiency per particle 
increases, along with a substantial red shift and broadening of the plasmon resonance 
peak [74, 191-194].  Figure 2.5 shows scattering spectra from a solution of isolated and 











2.6.2 Theoretical Descriptions 
The theoretical treatment describing scattered light from a sub-wavelength particle 
has been developed in various forms since at least the time of Lord Rayleigh.  This 
description is based on the presumption that the free electrons on the particle surface are 
induced to oscillate in a dipole at the same frequency as the impinging electromagnetic 
(EM) radiation.  This, in turn, produces a secondary EM field with the same frequency 
Figure 2.5.  Scattering increase and red 
shift of aggregated particles.  
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[159].  In the case of gold (and silver as well), the dielectric properties are such that an 
optimum wavelength exists, at the plasmon spectral peak (refer to figure 10), where the 
induced electric field will be the greatest.  Thus, if a population of particles is illuminated 
with a broadband light source, the particle will preferentially scatter certain wavelengths 
more than others in the optical range.  As stated before, this peak wavelength is a 
function of the particle material, size, shape, and the surrounding dielectric environment.   
The theory put forth by Lord Rayleigh in the middle of the 19
th
 century can accurately 
describe the dipole scattering of particles that are substantially smaller than the 
illumination wavelength.  It assumes that the electrons oscillate in unison, or that the 
dipole shows no phase shift across the dimension of the particle.  Although this is not a 
completely accurate description, the theory holds quite well for particles less than about 
40 nm [159].  Specific cases can be made for differing polarization schemes, but for the 
general case of unpolarized light impinging on a particle with a corresponding detection 
direction (defined by spherical coordinates θ, φ, and r), the detected intensity of scattered 




Where a is the particle radius, nmed is the refractive index of the surrounding media, I0 
is the impinging light intensity, r is the distance from the particle to the detector, λ0 is the 
impinging wavelength, and m is the relative refractive index of the particle (i.e. np/nmed).  
Since metal nanoparticles are both scatterers and absorbers, a complex refractive index is 
necessary to fully describe their interaction with light.  Although Rayleigh theory was 
originally put forth to describe purely scattering particles, it also holds for the case of 
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complex refractive indices.  And, if the dielectric function is large and negative, this 
indicates that the electric field in and around the particle will be greatly enhanced – thus 
pointing to the reason for the relatively large optical cross section.  To calculate this value 
directly, the above expression is integrated over all angles θ, and r is set to unity, the 
resulting expression is defined in terms of area.  This quantity is useful in describing the 
overall scattering efficiency of the particle, and its physical significance can be 





The expression indicates that the scattering cross section increases with the sixth 
power of the radius and decreases with the fourth power of the incident wavelength.  This 
would indicate a monotonic change in scattering with wavelength, but another 
determining factor in the overall spectral shape is the refractive index, whose absolute 
value reaches a peak in the optical range – corresponding to the plasmon resonance 
wavelength.  This wavelength indicates the frequency at which the electric field-induced 
oscillation of the conduction band electrons requires the least amount of energy to 
displace a given distance.  In general, larger particles of a given material have a more red-
shifted plasmon peak compared to smaller particles.  The presence of a surrounding 
media with a high refractive index will also serve to decrease this resonant frequency.  
Finally, irregularly shaped particles may have multiple resonances corresponding to 
oscillations along different geometrical axes of the particles – and thus the effective 
dielectric function will have a polarization dependency.   
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While useful, the Rayleigh description does not fully describe light interactions with 
isolated metal nanoparticles.  Besides its applicability to only a limited range of sizes, it 
also assumes that the only electric field perturbations experienced by the particles are 
caused by the incoming light.  It does not take into account the secondary electric fields 
produced by other nearby particles.  This would be needed if the aggregation effects are 
to be fully described theoretically.  To accomplish this, a more robust theory must be 
utilized.  In 1908, Gustav Mie put forth a rigorous solution to Maxwell’s equations for 
perfectly spherical scatterers [159].  This theory takes into account the phase differences 
in oscillating electrons across the dimension of the particle as a result of the coherent 
electric field impinging on it, as well as more complex oscillation modes such as a 
quadropole, octopole, etc.  This theory can be used to extrapolate the light scattering 
behavior from particles of a variety of geometries such as particles with concentric layers, 
aspherical particles, etc., although these treatments tend to be approximations.  While a 
rigorous analysis of this theory is beyond the scope of this dissertation, the basic Mie 
expression for scattering cross-section Csca of a spherical particle is given below: 
 
 
Where k is the wave number; n is the complex refractive index; and an and bn are 
defined by Bessel and Ricatti functions [159].  For those particles less than approximately 
1/20
th
 of the impinging wavelength, Mie theory can be simplified to the Rayleigh 
expression.  Several good sources are available for an in-depth analysis of Mie theory, 
including [159, 197].As stated previously, Mie theory may be adapted to calculate the 
resulting scattered electric field from a collection of closely spaced nanoparticles, or 
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alternatively, irregular shaped particles.  The discrete dipole approximations and T-matrix 
implementation are two widely used, but complex frameworks in which to address this 
phenomenon [198, 199].  An instructive exercise, however, can be made in the case of 
only two, small, interacting gold particles, as shown in figure 2.6.   
Figure 2.6(A) shows that when the electric field is oscillating orthogonally to the long 
axis of the particle pair, the induced dipole is such that charges of the same sign from 
each particle are always nearest each other.  This causes a charge repulsion effects 
between the two particles.  These repulsion effects tend to make the optimum oscillation 
frequency higher (but with damped amplitude), which results in a blue shifting and 
overall decrease in intensity of the plasmon peak.   In (B), the particle pair’s long axis is 
parallel to the oscillating electric field.  In this case, charges of opposite sign from each 
particle are nearest each other, resulting in a red-shifting and un-damping of the plasmon 
resonance, for the reasons explained above.  This explains why the red-shifting portion is 
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Figure 2.6. Plasmon coupling between two closely spaced gold nanoparticles. (A) When the 
electric field is oscillating orthogonally to the long axis of the particle pair, the induced dipole is 
such that charges of the same sign from each particle are nearest each other.  This causes a blue 
shifting of overall plasmon resonance.  (B) When the particle pair’s long axis is parallel to the 
oscillating electric field, charges of opposite sign from each particle are nearest each other, 
resulting in a red-shifting of the plasmon resonance. 
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While this can explain the red and blue-shifting of plasmons and their relative 
intensities, it does not fully account for the large, non-linear increase in scattering cross 
section seen gold nanoparticle aggregates.  To answer this, one must turn to coherent 
backscattering theory [200], which explains that for particles in dense clusters produce an 
effect, arising from the coherent constructive addition of the backscattered light, that 
results in a second-order increase in scattering cross-section with number of particles (for 
a given distance).  This means that the scattered light will increase as the square of the 
number of particles in an aggregate. Both the overall red-shifting and increase in overall 
scattering cross-section serve as powerful contrast enhancing mechanisms for molecular 
imaging.   
2.6.3 Synthesis and Bioconjugation 
The synthesis of nanometer-sized gold particles has been performed in a controlled 
environment since the 1950s, although the process was refined by Frens in the 1970s 
[201] and was believed to be performed by Faraday in the 1850s.  By far the most 
common approach to synthesis in solution has been the chemical reduction of a gold salt 
– usually HAuCl4 – to metallic gold in colloid form.  Various reducing agents have been 
utilized, the most common being citrate [201], although ascorbate [202], sodium 
borohydrate [203], and pure hydrogen among others.  In addition, other methods 
employing ultrasonication [204], electrochemical techniques [205], as well as 
lithographic strategies [206] have also been used in certain applications.  The chief 
concern when synthesizing colloidal gold is the control of size and size distribution.  This 
can be altered by the relative concentration of gold ions to reducing agents, as was shown 
by Frens [201].  The mechanism for this is presumed to be simple: In the Frens study, 
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citrate is hypothesized to act as a nucleating agent, as well as the reducer.  By lowering 
the citrate to gold ratio, there are fewer nucleation sites available for particle synthesis, 
and thus a given amount of gold must be reduced into larger particles at completion.  A 
larger number of nucleation sites translate to more, but smaller particles.  Of critical 
importance is the ability of the reducing agent to also stabilize the particles in solution 
from aggregation.  Polymers such as poly ethylene glycol (PEG) and poly vinyl 
pyrrolidone (PVP) have been used as adjuvant stabilizers to create longer-lasting 
colloidal solutions.   
Stabilization becomes particularly important when synthesizing other metal 
nanoparticle geometries.  To date, a dizzying array of nanoparticle shapes has been 
synthesized through a wide variety of methods to modulate and optimize particular 
optical properties.  Popular materials include nanorods [207], triangles [208], nanoshells 
[30, 209, 210], cubes/cages [211], and stellated nanoparticles [212]. 
Clearly, in order to target gold nanoparticles to a biological sample, conjugation of a 
biomolecular recognition molecule is essential.  The attachment of biomolecules to gold 
nanoparticle surfaces has been studied extensively, primarily as a means for molecular 
tagging in electron microscopy applications [67, 213-215].  It was shown that various 
proteins would physically absorb to the gold surface in a pH dependent manner, where 
the highest efficiency absorption occurred at or near that protein’s isoelectric point (pI) 
[68] .  Simple centrifugation enabled the separation of conjugated and unconjugated 
proteins.  More recently, it has been found that a stable bond between a thiol moiety and 
gold surfaces is formed under most conditions.  This was first reported as a method for 
preparing self-assembled monolayers (SAMs) onto planar gold surfaces [216], and was 
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adapted for conjugation to particle surfaces [217].  The gold-thiol reaction represents a 
flexible and powerful method for bioconjugation, producing bonds that are considered 
covalent in their strength. In either case, it is important to ensure that the bioconjugation 
of targeting molecules not interfere with their native function.  Fortunately, antibodies, 
which represent a powerful means of targeting, do not show this tendency.  Care must be 
taken, however, in the case of smaller peptides or nucleic acid sequences such that their 
conformation does not change to affect their utility.   
2.6.4 Optical Interrogation 
While the synthesis and bioconjugation of gold nanostructures remains an active area 
of research, their optical detection in a biological environment remains a paramount 
consideration.  Several modalities exist which are suitable for this purpose, and the 
selection of a particular method is often application specific.  Perhaps the simplest and 
first to be developed is darkfield microscopy.  This is an adaptation of brightfield 
microscopy which allows the detection of scattered light, while rejecting the primary 
illumination.  It involves illuminating the sample with an oblique cone of light such that 
the incident numerical aperture (as defined by the angle at which it is focused onto the 
sample) that is higher than the detection numerical aperture.  Thus, only higher 
diffraction orders are allowed to pass to the detection path of the microscope.  This can 
be accomplished either via a transmitted or epi-illuminated geometry, although the later 
requires a specialized objective that has a separate illumination and collection 
compartments.  The transmitted case is illustrated in figure 2.7.  Note the use of a dark 
field patch stop, which is essentially an absorbing annulus in the illumination path, in 
order to create a hollow cone of light that is focused at high NA.   
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This keeps the primary light from entering the objective, allowing only higher-order 
scattered light from being detected.  A similar setup is used in the epi-illuminated case, 
whereby light is focused through an outer annulus in a specialized objective, and 
collected through an inner annulus.Darkfield microscopy is useful, in that it allows 
excitation of the sample with a broadband light source.  However, the axial resolution 
attainable through this setup is determined by the focal volume of the objective, and as 
such, out-of-focus light is detectable.  For simple samples consisting of a single cell 
layer, this is generally sufficient to produce high-quality images.  However, for thicker 
samples, an optical sectioning modality is preferable.  As discussed previously, 
reflectance confocal microscopy or OCT can be used for this purpose.  Confocal 
microscopy is capable of optical sectioning with submicron resolution of samples that are 
Figure 2.7. Optical setup required for transmitted darkfield microscopy.  Note the dark field patch 
stop, which is essentially an absorbing annulus placed in the illumination path.  This creates a hollow 




several hundred microns to millimeters thick, under ideal conditions [145, 218, 219].  
However, most systems use laser illumination, and thus do not provide spectrally 
sensitive information in reflectance mode.  OCT systems can often penetrate deeper into 
tissues than confocal, but generally suffer from lower resolutions [53, 151]. 
To gain more detailed spectral information, traditional spectroscopy is an obvious 
option.  However, the lack of spatial information attainable in traditional spectroscopy 
begs the question as to whether a modality can be developed that will deliver both 
detailed spatial and spectral information.  As such, the emergence of hyperspectral 
imaging systems has been an exciting development [220].  This method refers to a set of 
instruments that are capable of collecting a three-dimensional data set of a sample of 
interest – i.e. two spatial and a spectral dimension.   
There are two commonly used setups that are used to achieve this.  The first utilizes 
Fourier spectroscopy concepts, adapted for imaging.  At its core, this type of system is an 
interferometer spectrometer, much like conventional FTIR spectrophotometers.  
However, while in the latter case, a single beam of light is passed through the sample and 
projected through the interferometer, the hyperspectral imaging device projects the 
sample image through the interferometer.  By modulating the path length difference 
(PLD), an interferogram is constructed and imaged using a CCD camera.  Simple FFT 
algorithms then extract the spectrum at each pixel [221].  Another, more direct method of 
hyperspectral imaging relies on simply segmenting a two-dimensional image into one-
dimensional components, and spectrally dispersing each in series.  In a typical setup, a 
slit is placed in the detection path of a microscope, which is projected through the 
detection path onto a dispersive prism or grating.  At this point, the one-dimensional 
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“slice” is dispersed into a two-dimensional spectrum onto a CCD detector.  This process 
can be repeated by serially scanning the sample across the slit using a controllable 
translation stage, building a three-dimensional data set [222]. 
The relevant considerations in utilizing hyperspectral imaging include acquisition 
times, as well as spatial and spectral resolutions.  In the past, Fourier based systems 
offered better signal-to-noise as compared to dispersive systems, mainly due to the fact 
that the entire spectral bandwidth of the sample is imaged at once, and repeated for 
different interferometer path length differences.  However, the drawback remains that 
these systems tend to necessitate many acquisitions to produce a data set, and suffer from 
limited spectral resolution.  More recently, however, CCD technology has advanced 
sufficiently that dispersive instruments can now offer comparable SNR, with superior 
spectral resolution.  In either case, this modality remains a powerful technique.  Indeed, 
with the combination of confocal microscopy, hyperspectral imaging can produce images 
with x, y, z, and wavelength resolved signal for a complete four dimensional 
characterization of a sample [223].  Such advanced imaging systems may in the future 
provide a complete characterization of nanoparticle labeled biological tissues for 
diagnostic and screening purposes by giving invaluable insight into the nanoscale 
arrangement of biomolecules within the cellular architecture.  
2.7 RELEVANT LITERATURE SYNOPSIS 
Though a relatively recent area of active research, the use of metal nanoparticles for 
optical molecular imaging has been proposed since the 1970s, due to their characteristic 
interactions with light, and favorable conjugation properties [224].  The first wide-spread 
uses of gold nanoparticles as optical detection tools were not, in fact, aimed at exploiting 
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their scattering properties, but rather the enormous multiplication of Raman signals due 
to the electric field enhancement apparent at the particle surface [225].   Their enhanced 
elastic scattering properties were not fully explored for biological detection until 
beginning in the late 1990s. Yguerabide et al. were able to demonstrate this approach 
convincingly in several landmark studies [70, 189, 226]  whereby gold nanoparticles 
were shown to be effective reporters in DNA assays, cell surface protein detection assays, 
as well as in-situ hybridization studies.  Schultz, et al., also showed the utility of this 
concept in similar studies (published nearly simultaneously), and demonstrated the multi-
color, spectral tuning capabilities of this technique in similar model biological assays 
[63].  It is also important to note that it had previously been shown that DNA-directed 
nanoparticle binding could detect DNA mismatches via temperature cycling down to a 
single nucleotide base pair in a simple, non-microscopic colorimetric assays [73, 227], 
which indirectly showed the powerful possibilities of exploiting the distance-dependent 
optical properties of gold nanoparticles. This has spawned a plethora of studies utilizing 
gold nanoparticles as powerful agents for various studies of nucleic acid detection [228-
241].  Of particular note is the is the work by Soennichsen, et al. who quantitatively 
demonstrated the phenomenon of plasmon coupling for determining DNA sequence 
length, to nanometer resolution [71].   
For proteomic based studies, work by Sokolov, et al. showed the ability to image 
EGFR expression in a variety of vital biological samples, including live cells, tissue 
phantoms, and live ex-vivo tissue samples  [195].  Since then, similar studies have 
followed using similar technologies for EGFR imaging [79, 81]. 
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As an alternative to pure gold nanoparticles, Liz-Marzan, et al. were first able to 
successfully synthesize gold-silica core-shell nanoparticles, followed by work by the 
others [30, 209, 210].  These particles (termed nanoshells) are attractive, as the dielectric 
inclusion within the noble metal shell causes a marked and controllable red-shift of the 
plasmon resonance into the NIR region, making detection into deeper tissues easier.  
Since then, growth factor receptor imaging has been accomplished by Loo, et al. in breast 
cancer cell lines [32, 33].  These studies have also shown the possibility to exploit the 
light absorption properties of nanoshells.  This absorption causes a local heating affect 
near the particle surface which can be harnessed to cause photothermal destruction of 
cellular tissue [242].  Because of this, a combined detection and therapy approach using 
plasmonic nanoparticles has become an intense area of interest, utilizing other particle 
geometries [243]. The work described above serves to illustrate the emerging breadth of 
the field of optical nano-biotechnology. 
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Single Cell Studies of EGFR Detection Using Gold Nanoparticles* 
3.1 ABSTRACT 
The use of metal nanoparticles has been recognized as a potential tool for molecular 
imaging, particularly in detection of carcinogenesis, as well as concurrent photothermal 
therapy of the same tissue.  In the last several years, studies have shown that the remitted 
optical signal from cells can be enhanced with the use of plasmonic nanoparticles, and 
with the addition of antibody targeting, molecular-specificity can be achieved.   However, 
the concept of plasmon coupling has been ill-explored as a mechanism for this 
enhancement.  While plasmon coupling has been utilized in some studies of DNA 
hybridization and enzymatic cleavage [71, 72], its implications have not been fully 
elucidated.  Further, plasmon coupling has not been utilized previously for molecular 
imaging in living cells.  The contents of this chapter serve to provide foundational studies 
and observations for satisfactorily characterizing plasmon coupling for detection of 
epidermal growth factor receptor (EGFR) in suspensions of single cells.  These results 
show that labeling EGFR with immuno-targeted gold nanoparticles results in protein-
mediated clustering of the particles on the cell surface.  This, in turn, produces a more 
than 100nm shift in the plasmon resonance wavelength as compared to isolated particles, 
as well as a non-linear increase in scattering intensity with respect to the number of 
                                                 
* The contents of this chapter have been published in Cancer Res. 63, 1999-2004, (2003), and J. Biomed. Opt. (2007), (in press). 
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clustered particles.  The result is highly enhanced optical signals (up to an order of 
magnitude increase) in the red and NIR spectral regions. In addition, the spectral 
information contained in these signals can potentially yield information not only about 
EGFR over expression, but also the nanoscale relationship among these receptors in the 
cell membrane.  These observations serve to prompt further questions as to the specific 
molecular trafficking and interaction events that are responsible for nanoparticle 
clustering, as well as providing critical insight for later use in more complex biological 
models of carcinogenesis.  
3.2 INTRODUCTION 
A number of different types of nanoparticles have recently been proposed for use as  
optical imaging agents to aid in cancer detection, including quantum dots (qdots) [180-
182], nanoshells [244], and metal nanoparticles [70]. The use of nanoparticles for 
molecular imaging of cancer has several important advantages. Their surface chemistry is 
well understood, so that they can be easily targeted using antibodies or aptamers to bind 
to cancer biomarkers. By adjusting the particle geometry, the optical properties can be 
tuned over a large spectral region to provide multi-color labeling. The bright reflectance 
or luminescence of nanoparticles provides a strong source of signal for in vivo imaging. 
Finally, multiplexing different types of particles and targeting molecules provides a 
common platform for multiple applications with a high degree of flexibility [181].  
Each nanoparticle type has inherent merits, and the selection of an appropriate tool 
will certainly be application-dependent.  As discussed previously, metal nanoparticles 
have several advantages for a number of applications.  These include large plasmon-
dependent signal and absorption cross-section, photostability, ease of synthesis, non-
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toxicity, ease of conjugation, and most importantly, the tendency to shift their optical 
properties in the presence of other particles.  In this way, metal nanoparticles offer an 
intriguing opportunity to probe and monitor the molecular and cellular events of 
tumorigenesis in real time via light scattering [34, 81, 195, 245], as well as the ability to 
therapeutically impact diseased tissue via light absorption [32, 77, 242]. Gold 
nanoparticles have been extensively used as molecular specific stains in electron 
microscopy, as well. As a result, the fundamental principles of interactions between gold 
particles and biomolecules have been thoroughly studied for more than 20 years [68, 
224].  The ability to resonantly scatter visible and NIR light, however, has not been 
extensively explored for vital microscopy in living specimens.  
In particular, the focus of these studies is to establish the principles of metal 
nanoparticle plasmon coupling as a tool for molecular imaging. The main tool in these 
studies are bioconjugates of gold nanoparticles with monoclonal antibodies against 
EGFR, a transmembrane 170 kDa glycoprotein that is overexpressed in epithelial pre-
cancers [100, 102, 113, 246-251] for molecular specific optical imaging. A high level of 
EGFR expression is often associated with enhanced aggressiveness of epithelial cancers 
and poor prognosis [102, 252, 253].  In these studies we used c. 20-25 nm diameter gold 
nanoparticles.  This size is approximately the same as the size of antibodies, which are 
routinely used for molecular specific labeling and targeting.  However, there are a 
number of barriers to achieve robust use in a clinical, in-vivo application, including 
development of: (1) molecular-specific bioconjugates that can be safely used in humans; 
(2) delivery formulations for these contrast agents in vivo; and (3) cheap, flexible 
imaging tools.  It seems likely that such a comprehensive strategy requires that a step-
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wise approach, using increasingly complex models, be used in evaluating the utility of 
such a strategy.   To that end, the contents of this chapter will be limited to studies using 
the simplest living eukaryotic model – cell suspensions.  This relatively simple, 
reproducible, and highly flexible model represents a reasonable position in which to 
begin studies. 
This chapter enumerates several important developments, observations and 
implications of using immuno-targeted gold nanoparticles on simple cell suspension 
models as a first testing ground for exploring plasmon coupling in living systems.  
Initially, the conjugation strategies used to link metal nanoparticles to the targeting 
monoclonal antibody are discussed in detail.  In addition, the strengths and weaknesses of 
the various optical modalities used in this chapter’s studies are also enumerated. Later, 
darkfield and confocal images of labeled and unlabeled cells are shown to qualitatively 
indicate the scattering intensity and spectral changes that occur when labeling cancer 
cells, particularly as a result of the aggregation of particles on and near the cell 
membrane.  These aggregation-dependant changes are quantified on a cell-by-cell basis 
using hyperspectral imaging. The presence of particle aggregation on the cell surface is 
confirmed by electron microscopy imaging.  
3.3 MATERIALS AND METHODS 
3.3.1 Conjugation of Anti-EGFR Antibodies to Gold Nanoparticles 
 Two main antibody clones were used in these studies as targeting molecules.  The 
first, anti-EGFR clone 225 is widely available as a therapeutic agent which blocks EGF 
and other ligand binding sites [254] on the extracellular domain of the receptor.  The 
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other clone, 29.1, similarly targets the extracellular portion, but localizes to a glycol-
moiety such that it does not block ligand binding [255], and was chosen to minimize any 
biological modulation from antibody binding.   
There were two main strategies used for linking the antibodies to the gold 
nanoparticle surface:  (1) Physical absorption and (2) covalent linkage.  Traditionally, 
physical absorption of antibodies has been by far the simplest and most widespread 
strategy used, particularly when preparing immuno-targeted gold particles for electron 
microscopy applications [68, 97].  A typical protocol involved the following steps:  0.1 
mg/mL of anti-EGFR antibodies in a 40 mM HEPES buffer, pH 7.4, were mixed for 20-
30 minutes with an equal volume of 25nm gold nanoparticles (which were prepared using 
the aforementioned citrate reduction method [201]. Conjugates were centrifuged at 3000 
rcf for 1-1.5 hours in the presence of 1% PEG and re-suspended in a PBS buffer, pH 7.4 
containing 1% BSA and 0.2% PEG as stabilizers. 
More recently, covalent strategies have been developed to improve the conjugation of 
proteins to noble metal surfaces.  In particular, the gold-thiol reaction has been widely 
exploited as a means for creating self-assembled monolayers (SAMs) [256], and can be 
adapted for conjugating antibodies to gold nanoparticles.  For experiments using 
covalently conjugated particles, the following protocol was used:  Antibodies were 
attached to gold nanoparticles via a conjugation linker that consists of a short 
polyethylene glycol (PEG) chain terminated at one end by a hydrazide moiety, and at the 
other end by two thiol groups.  First, antibodies at a concentration of 1mg/mL were 
exposed to 10mM NaIO4 in a 40mM HEPES pH 7.4 solution for 30-40 minutes at room 
temperature, thereby oxidizing the hydroxyl moieties on the antibodies’ Fc region to 
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aldehyde groups. The formation of the aldehyde groups was colorimetrically confirmed 
using a standard assay with an alkaline Purpald solution (Sigma). Then, excess 
hydrazide-PEG-thiol linker was added to the oxidized antibodies and allowed to react for 
20 minutes. The hydrazide portion of the PEG linker interacts with aldehyde groups on 
the antibodies to form a stable linkage. In this procedure a potential loss of antibody 
function is avoided because the linker can not interact with the antibody’s target-binding 
region, which contains no glycosylation. The unreacted linker was removed by filtration 
through a 100,000 MWCO filter (Millipore).  After purification, the modified antibodies 
were mixed with gold nanoparticles in 40mM HEPES (pH 7.4) for 20 minutes at room 
temperature. During this step a stable bond is formed between the gold surface and the 
linker’s thiol groups.  Afterward, monofunctional PEG-thiol molecules were added to 
passivate the remaining nanoparticle surface.  Finally, the conjugates were centrifuged at 
2800 rcf for 45 minutes and resuspended in 1x PBS, producing a solution containing 
approximately 10
12
 particles per mL.  In either case, conjugation of biomolecules to gold 
nanoparticles can be independently detected using UV-Vis spectroscopy by a 3-5nm red-
shift in the plasmon peak position between bare and conjugated particles.  This is due to a 
increase in the effective refractive index surrounding the particle [159].  Bifunctional 
contrast agents were synthesized via a monoclonal antibody labeling kit (Molecular 
Probes) to attach Alexa Fluor 488 dye to purified antibodies. Then, fluorescently labeled 
antibodies were conjugated with gold nanoparticles as described previously. 
3.3.2 Cell Cultures 
All cells were cultured in DMEM or MEM plus 10% FBS and grown at 37ºC in 5% 
CO2.  There were three main EGFR over-expressing cell lines used in the various studies:  
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(1) A-431 cells are an epidermoid keratinocyte, which expresses on the order of 10
6
 
EGFR molecules per cell, (2) MDA-MB-468 cells, which are a breast epithelial line 
derived from a ductal carcinoma and also express c. 10
6
 EGFR/cell, and (3) SiHa, a line 
derived from a squamous epithelial carcinoma of the cervix, expressing c. 10
5
 EGFR/cell. 
Cells were harvested using exposure to conventional buffered trypsin-EDTA, containing 
Phenol-red (Gibco) for 5 minutes at 37°C. After washing in phenol-free media, cell 
suspensions were labeled in a 50:50 (v/v) mixture of phenol/serum free DMEM and 
contrast agents for 30 minutes at room temperature, before being washed and 
resuspended in pure phenol-free media. 
3.3.3 Optical Imaging  
Reflectance confocal images of cells were acquired using a Leica TCS-4D confocal 
microscope using with 647 nm illumination under 40x objective magnification, with NA 
of 0.8.  Darkfield and fluorescence imaging of cells was performed using a Leica 
DM6000 upright microscope configured with a 20X, 0.5/0.95 collection/illumination NA 
darkfield objective, fluorescence filter cubes (Chroma), and a 75W Xe light source. RGB 
images were captured using a Q-Imaging Retiga EXi CCD camera with color LCD 
attachment. Hyperspectral images were captured with either a SpectraCube
®
 spectral 
imaging camera (Applied Spectral Imaging), using a Fourier spectroscopy based 
approach or a PARISS
®
 hyperspectral imaging device (LightForm, Inc.), which uses a 
prism dispersion based technique. Bifunctional contrast agents were imaged with 633 nm 
excitation and 650-700 nm emission bandwidth. Imaging of hamsters in vivo was carried 
out using a portable reflectance confocal microscope which is described in. 
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3.3.4 Scanning Transmission Electron Microscopy  
Labeled A-431 cells were absorbed onto a gold/carbon film grid and dehydrated in a 
5-part water/ethanol series for 50 minutes. After light fixation in 2% glutaraldehyde for 
an additional 10 minutes, samples were then subjected to a 5-part ethanol/acetone 
exchange for another 50 minutes at room temperature.  This allowed for the sample to be 
placed in an automated CO2/acetone critical point drying apparatus (Samdri-790, 
Tousimis, Corp.) which makes it possible to avoid surface tension-induced disturbances 
of the cell surface [257]. Cells were imaged with a JEOL 2010F STEM equipped to 
image in Z-contrast mode. A HAADF detector (50 – 110 mrad) was used for image 
acquisition with a probe size of 0.2 nm. In addition, the JEOL STEM system contains 
atom-level probes connected to an Oxford INCA Energy Dispersive Spectrometer (EDS) 
to positively identify the presence of gold on the cellular surface. 
3.3.5 Image Analysis 
All images were analyzed using NIH ImageJ.  Regions of interest were manually 
segmented; background signal was evaluated from an area that contained no cells, and 
was subtracted; then, the non-zero pixel values were isolated and the mean was evaluated 
to calculate average intensity and contrast values.    
3.4 RESULTS 
3.4.1 Confocal Imaging of Cells Labeled with Anti-EGFR Conjugates 
Confocal microscopy is a widely used optical imaging modality, [258-260], as its 
high resolution, both in the lateral and axial directions, renders it attractive in biological 
studies [219] .  The improved axial resolution is a result of a pinhole located at the 
conjugate image plane, as well as the scanning action of the illumination/excitation laser 
[261], which allows for an “optical sectioning” ability that gives three-dimensional 
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information. To evaluate whether confocal reflectance imaging can be used to detect 
differences in scattering due to EGFR-labeling using gold nanoparticles, Figure 3.1 (A-
D) shows confocal reflectance images (left column) and combined 
transmittance/reflectance images (right column) of SiHa cervical cancer cells labeled 
with anti-EGFR/gold conjugates for 45 minutes at room temperature. In a series of 
through focus confocal reflectance images of labeled cells, the bound conjugates first 
appear as randomly distributed bright spots at the top of the cells (A and B), then bright 
rings can be seen in the optical cross-sections through the middle of the cells (C and D).  
The labeling pattern is consistent with the fact that the monoclonal antibodies have 
molecular specificity to the extracellular domain of EGFR. The intensity of light 
scattering from the labeled SiHa cells is ca. 50 times higher than from unlabeled cells, as 
determined by image analysis. Therefore unlabeled cells cannot be resolved on the dark 
background. Similar results were observed when gold conjugates with bovine serum 
albumin (BSA) were added to the cells (Figure 3.1, E and F), further bolstering the 
contention that the conjugates are bound specifically to the EGFR contained in the cell 
membrane.  These negative controls also displayed 30-50 fold less signal than labeled 
cells. 
We also conducted reflectance imaging before and after the unbound gold conjugates 
were washed from the cell suspension (data not shown). The unbound gold particles were 
not detectable in confocal either before or after washing.  This is an important 
observation, as it indicates that in the red optical region, the particles on the cell surface 
are considerably brighter than any that might exists in the extracellular space, consistent 
with the aggregation-dependent red-shift in plasmon peak position and coherence-based 
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scattering efficiency increases described in the previous chapter.  However, broadband 






















3.4.2 Darkfield Imaging of Cells Labeled with Anti-EGFR Conjugates 
To better illustrate this effect on the cell surface, SiHa cells were labeled with 25nm 




Figure 3.1 Laser scanning confocal reflectance (A, C, and E) and combined confocal 
reflectance/transmittance (B, D, and F) images of the labeled SiHa cells obtained with 
40X objective. In (A) and (B) the focal plane is at the top of the cells.  In (C) and (D) 
the middle cross-section of the cells is in focus.  The confocal reflectance and 
transmittance images were obtained independently and then overlaid.  Non-specific 
labeling using gold conjugates with BSA is shown in E and F.  Note the absence of 
cell labeling after exposure to non-specific conjugates. The scattering from gold 
conjugates is false-colored in red.  Images were obtained with 647 nm laser excitation.  
The scale bar is ca. 20 µm (A-F). 
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light illumination with a 75W Xenon source.  Because of the broad-band nature of this 
illumination, the resonant scattering behavior of nanoparticles is much more apparent 
relative to laser illumination.  Figure 3.2A shows the natural scattering appearance of 
SiHa cells, while figure 3.2B shows the same cell line after labeling with anti-EGFR gold 
conjugates. This figure illustrates two important phenomena.  First, the gold nanoparticles 
dramatically increase the overall optical scattering signal from cells.  Figure 3.2A was 
acquired at 3 times the exposure time as figure 3.2B in order for both cell populations to 
be visible above the background in the images.  Secondly, the gold nanoparticles produce 
a marked color change in the SiHa cells.  As is indicated by the green arrow, portions of 
the cell appear green, consistent with the plasmon peak of approximately 530nm seen in 















Figure 3.2 (A) unlabeled SiHa cells and (B) SiHa cells labeled with contrast agents 
for 45 minutes at room temperature.  Darkfield images under white light illumination 
show the color change associated with gold nanoparticle labeling of EGFR on SiHa 
cervical cancer cells.  In (B), Note that some portions of cells are green in color, 
consistent with the optical properties of a relatively disperse population of 
nanoparticles (indicated by green arrow).  However, other portions of cells appear 
orange-red, indicative denser aggregation of particles, which produces a red-shift in 
the plasmon peak, as well as increased per-particle scattering efficiencies.  It is 
important to note that (A) was acquired at 3 times the exposure time as (B). Scale 
bar is c. 20µm.   
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In addition, however, other portions of the cells appear a distinct orange-red 
(indicated by red arrow).  This is highly consistent with measurements taken of solutions 
of aggregated gold nanoparticles, whose plasmon peak is broadened and shifted to the 
600-650nm range (relative to isolated particles).   
3.4.3 Hyperspectral Imaging of Labeled and Unlabeled Cells 
These observations, however, are better supported by a spectral analysis of the optical 
signals from labeled cells.  To do this, however, requires an increased level of 
sophistication.  To that end, we coupled a hyperspectral imaging device (SpectraCube, 
Applied Spectral Imaging, Inc.) to the darkfield microscope.  This Fourier-based imaging 
spectrometer enables a precise intensity vs. wavelength relationship to be measured at 
each 2D pixel position in the darkfield image, thus creating a three-dimensional data set 
for each field of view.  In this way, a very detailed description of the scattering signal 
(localized within a single cell) can be shown.  Figure 3.3 shows a typical comparison 
between scattering spectra from a labeled cell and compared with spectra from a cell not 
exposed to contrastagnets, shown by the red and green curves, respectively.  Note that in 
the case of the unlabeled cell, the scattering profile shows a monotonic decrease in 
scattered light vs. wavelength, which is predicted in the case of light scattered from a 
dielectric sphere [159], and has been also observed in living cells [152].  Spectra from 
labeled cells (shown in red) display a prominent resonance peak at approximately 650nm.  
This is highly consistent with independent bulk UV-Vis measurements of aggregated 
nanoparticles [195], and represents a more than 100nm red-shift in the peak scattering 























3.4.4 Quadratic Dependence of Scattering Efficiency on Aggregate Size 
While the dramatic color changes associated with plasmon coupling on the cell 
surface serve to act as a powerful contrast enhancing mechanism, the increase in overall 
scattering efficiency per particle is equally important.  As stated before, the wavelength-
integrated scattering cross section can be shown to be proportional to the number of 
particles in an aggregate squared [262].  To characterize this non-linear scattering 
intensity increase associated with metal nanoparticle plasmon coupling, the following 
experiment was devised:  EGFR-over expressing A-431 epidermoid keratinocytes were 
labeled with bifunctional contrast agents, consisting of a fluorescently-tagged antibody 
which was then conjugated to the gold nanoparticle.  Thus, the contrast agent will 
produce both a relatively strong fluorescence signal and a characteristic scattering profile.  
To a very good approximation, the fluorescence signal will be proportional to the number 
Figure 3.3 Hyperspectral data taken from a labeled cell (red line) and 
unlabeled cell (green line) under darkfield illumination.  Note that the 
scattering signal from the unlabeled cell follows a characteristic 
inverse-power type profile indicative of scattering from a dielectric 
particle.  The labeled cell, however, displays a prominent peak at 
approximately 650nm, consistant with bulk UV-Vis measurements of 
aggregated gold nanoparticles.     
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of gold nanoparticles in a given imaging volume, as the degree of fluorescence labeling 
of the antibody is a highly controlled reaction.  Cells are then imaged in both darkfield 
and fluorescence modes in an identical field of view.  These two images were then 
compared on a pixel-by-pixel basis. The Leica DM6000 was used both both modalities, 
as the illumination turrent has been evaluated to produce a zero-pixel shift when 
switching between illumination modes.  It was assumed that the fluorescence image pixel 
value was proportional to the number of fluorophors in that imaging volume, as thus also 
the number of nanoparticles in that volume.  The darkfield image pixel intensity is 
proportional to the total scattering cross-section of particles in the same volume.  This 
assumption provides a way to compare the scattering intensity of nanoparticle aggregates 
as a function of the number of particles in that aggregate.  The results are plotted in figure 
3.4 below, and show a range of fluorescence and darkfield pixel values from an image of 
A-431 cells labeled with bifunctional contrast agents (see inset).   
The range of fluorescent pixel values is due to a range of particle concentrations from 
pixel to pixel, while the range of darkfield values (which is taken as a sum of the three 
RGB channels) indicates a corresponding range of degree of aggregation.  Each pixel, 
with an area of 0.1 µm
2
 at 20x magnification, can potentially contain nearly 100 particles 
if closely packed, thereby allowing a wide range of possible aggregation states in each 
pixel.  The resulting pixel-by-pixel plot shows a non-linear increase in scattering as a 
function of number of nanoparticles, which agrees with the theoretically predicted 
quadratic increase with a R
2



















3.4.5 Electron Microscopy of Labeled Cells   
The results shown in figures 3.1-3.4 are highly consistent with a nanoscale 
aggregation of gold particles on the cell surface.  However, to independently confirm that 
this phenomenon is occurring, A-431 cells were labeled, dehydrated, fixed, and subjected 
to a critical point drying procedure, as outlined in the Materials and Methods.  The 
critical point drying procedure occurs in a CO2/Acetone system whereby acetone is 
converted from liquid to gas without a large change in surface tension.  This allows for 
the cells to dry intact, without any surface tension-induced disturbances of the cell 
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Figure 3.4 Labeling of cancer cells: quadratic dependence of total scattering cross section 
on the number of anti-EGFR gold conjugates.  The inset displays fluorescence (left) and 
darkfield reflectance (right) images of A431 cells labeled with anti-EGFR antibodies 
conjugated to a fluorescein derivative and gold nanoparticles. The plot shows the 
relationship between the reflectance intensity from each pixel in the darkfield image and the 
fluorescence intensity from exactly the same pixel in the fluorescence image (●).  The 
experimental data agree well with the theoretically predicted quadratic dependence of 
scattering cross-section on number of nanoparticle (R
2
 = 0.85; solid curve).  The observed 
variations in the intensity of the darkfield pixel values can be explained by the accuracy of 
the optical measurements with 8 bit CCD camera.   
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surface [257].   After drying, the cells were imaged using a high angle annular dark field 
scanning electron microscope (HAADF STEM).  This imaging modality detects scattered 
electrons (rather than the conventional transmitted component), and can ‘tune’ its 
detection angle for increased sensitivity to electron scattering from specific atomic 
species.  This allows an image that has a heightened contribution from electrons scattered 
by gold atoms only, often referred to as Z-contrast [263].  A representative image is 
shown in figure 3.5.  It shows the surface of A-431 cells labeled with 25nm gold particles 
conjugated to anti-EGFR antibodies (clone 29.1), as described in section 2.1.  The 
particles appear as white circles, while the cell membrane appears as a more diffuse 
background.  Note that some of the particles display a distinct “pairing” tendency, highly 
suggestive of the EGFR dimerization model of activation, although more definitive 










Figure 3.5 Z-contrast scanning transmission electron microscopy (STEM) of 
whole cancer cells labeled with anti-EGFR gold nanoparticles (A and B). Gold 
conjugates appear as white spheres. White circles in (A) highlight dimers of gold 
nanoparticles which reflect dimerization of EGFR molecules. 
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3.5 DISCUSSION 
It is known that the optical properties of metal nanoparticles undergo dramatic 
changes when two or more particles are in close vicinity [191] to each other. These 
include an increase in scattering cross-section per particle and a red shift in the plasmon 
resonance frequency (color change). Recently, these properties were exploited to develop 
ultrasensitive assays in vitro [70, 71, 73, 264-266], as well as a mechanism for increased 
photothermolysis efficiency [267]. Some of the most promising directions in this area 
focus on exploiting plasmon resonance coupling between adjacent nanoparticles for DNA 
probe assays [71, 73, 266]. However, these phenomena have yet to be fully exploited for 
use in molecular imaging in living tissue.  In an attempt to study the principles involved 
in the detection of EGFR on the cell surface, we used cancer cells labeled with anti-
EGFR gold conjugates to demonstrate how these non-linear optical properties can 
translate into high contrast molecular imaging of cancer biomarkers in living cells.  
As shown by electron microscopy, EGFR-bound gold nanoparticles on the cell 
surface display an aggregation effect suggestive of pre-endocytotic trafficking of EGFR 
into clathrin-coated pits [268], although more precise determinations of particle 
localization are investigated further in the next chapter.  Overall, the protein-mediated 
nanoparticle aggregation results in plasmon coupling between gold bioconjugates, 
producing a spectral shift of more than 100 nm in light scattering of the nanoparticles. In 
addition, coherent scattering effects result in a quadratic increase in the total scattering 
cross-section of closely spaced nanoparticles. This occurs because an assembly of 
nanoparticles manifests an electric polarization in response to the incident electric field. 
The magnitude of this polarization is proportional to the magnitude of the incident field 
and also to the total number of nanoparticles. The scattered electric field is proportional 
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to this polarization, and therefore the scattered power and the scattering cross-section are 
proportional to the square of the number of the particles in the aggregate.  
The combination of the plasmon red shift and the non-linear increase in the total 
scattering cross section of aggregates leads to a large increase in the scattering signal 
from labeled cells in the red optical region, with limits of resolution in the range of 100-
500nm, depending on the magnification. This allows simple optimization of the 
excitation wavelength for detection of highly EGFR-overexpressing cells, even in the 
presence of isolated gold bioconjugates, resulting in more than an order of magnitude 
increase in remitted signal. Additionally, the large red optical shift in the plasmon 
resonances provides the possibility to decrease the contribution from the endogenous 
scattering of cells which is predominant in the blue spectral region.  These results can 
serve as a basis for further investigations using more complex biological models that 
more closely resemble in-vivo tissue.  Critical questions remain, however, as to the 
specific mechanisms by which the protein-induced plasmon coupling occurs within living 
cells. These include the role of EGFR dimerization, aggregation, endocytosis, as well as 
other trafficking events. 
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CHAPTER 4: 
EGFR Trafficking and Mechanisms of Nanoparticle Aggregation 
4.1 ABSTRACT 
We show that immuno-targeted gold nanoparticles are exquisitely sensitive to the 
nanoscale spatial arrangement of EGFR molecules in cultured A-431 cells.  Darkfield 
imaging of cells maintained in a live imaging chamber show a clear spectral shift in 
scattering properties (easily visible in a color CCD camera) upon contrast agent binding 
to the cell surface.  Interestingly, red-shifting of the nanoparticles’ plasmon resonance 
occurs over a longer period of time (on the order of 30-60 minutes, depending on particle 
concentration and temperature), even after removal of excess particles from the 
surrounding solution.  This likely indicates that endocytotic internalization of EGFR 
molecules is responsible for shifting nanoparticle aggregate plasmon resonance into the 
near infrared spectral regions.  Transmission electron microscopy supports this claim.  
Finally, through temperature modulation, the aggregation state of EGFR-bound 
nanoparticles can be controlled for detailed spectral measurements. Statistical 
distributions of peak wavelengths from hyperspectral imaging data delineate different 
localization states, from primarily on the cell membrane, to early endosomal formation, 
and finally entry to mature lysosomes.  These states are independently controlled via 
temperature.    
4.2 INTRODUCTION 
 As the results from previous chapters indicate, the phenomenon of surface plasmon 
coupling is central to understanding the contrast enhancement properties of gold 
nanoparticles as EGFR-specific labels.  These studies show a clear red-shifting of the 
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plasmon resonance on the cell surface relative to particles in solution.  This, together with 
coherent scattering effects [200], produces optical signatures from cells which are redder 
and brighter than those seen in solution.  This is supported by several highly controlled 
studies of particle pairs, whereby spectral shifts are measured as a function of  particle 
size and spacing [71, 72, 191, 269]. 
The aforementioned data in cells are indicative of higher-order aggregation – i.e. 
many particles in close proximity to each other, not isolated particle pairs, as evidenced 
by the large spectral red-shift.  Pairs of gold particles typically display spectral shifts of 
less than 10nm, while aggregates on the cell surface can show as much as a 100nm shift.  
While the discrete dipole approximation and T-matrix theory can give us good inferences 
as to what can be expected in these highly complex arrangements [194, 198, 199], a fully 
robust and generalized optical behavior theory of arbitrarily aggregated nanoparticle is 
still under development.  As such, we must rely on experimental measurements to 
correlate the observed optical property shifts with the behavior of EGFR molecules in 
and on the cell.   
This affords a good opportunity, however, to postulate causal relationships between 
what is known of EGFR signaling and trafficking behavior and the resulting optical 
signatures seen in the data.  As has been elucidated over 25 years of molecular biological 
studies, EGFR can undergo several stages of compartmentalization during its life-cycle, 
depending on the cell type in question.  Early studies found that clusters of EGFR formed 
on proliferating cells, and this clustering could be controlled by external parameters, such 
as temperature [129, 131].  While homo- and hetero-dimerization has since been found to 
be a mode by which tyrosine phosphorylation generally occurs [105], the role of receptor 
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clustering has been postulated to act as an organizational event closely tied to endosomal 
uptake, and eventual lysosomal degradation or recycling as an important  part of the 
EGFR signaling and regulatory process [97, 135, 137, 138, 270-272].   
4.3 MATERIALS AND METHODS 
4.3.1 Anti-EGFR Contrast Agents 
25nm gold nanoparticles were synthesized according the method by Frens [201], and 
conjugated using the dithiol-hydrazide bifunctional PEG linker (Sensopath Technologies, 
Inc.) described in the previous chapter.  Briefly, anti-EGFR antibodies (clone 29.1.1, 
Sigma) were purified and oxidized for 30 minutes in 100mM NaIO4, before being 
exposed to an excess of the bifunctional linker for an additional 30 minutes.  This clone 
has been shown to not block ligand binding [255]. Non-reacted linker was removed via 
centrifugal reverse osmosis in a 100kD MWCO filter (Centricon).  Gold nanoparticle 
conjugates were stored in 1x PBS at a particle concentration equal to twice that at which 
the original particles were synthesized at (approximately 2 x 10
12
 particles per mL).   
4.3.2 Cell Culture and Labeling Procedure 
EGFR overexpressing A-431 epidermoid carcinoma cells were grown in Dulbecco’s 
Modified Eagle Media (DMEM), plus 10% FBS at 37°C in a 5% CO2 atmosphere.   This 
cell line has been extensively studied with regards to the behavior of EGFR both on the 
plasma membrane, and within the cytosol [83, 97, 133, 273, 274].  Adherent cells were 
cultured on 22mm square coverslips, and washed in phenolphthalein-free and serum-free 
serum prior to labeling to minimize receptor activation before labeling.  Exposure to 
conjugates occurred for 30 minutes under mild agitation at 4°C, 25°C, and 37°C. To 
preserve the temperature-mediated EGFR organization, after labeling, cells were 
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immediately fixed in 10% buffered formalin for 15-20 minutes, and then extensively 
washed and stored in 1x PBS.  
Cells labeled adherently in the imaging chamber were cultured on sterilized 40mm 
circular glass coverslips (Bioptechs, Inc.), and affixed in a custom designed imaging 
chamber.  Adherent cells were labeled with a 1:4 mixture of 1x PBS/contrast agent and 
serum- and phenolphthalein-free media at 25°C that was injected into the chamber.  The 
lower concentration was used to help reduce the background signal from unbound 
conjugates. Pure DMEM was subsequently injected in excess to clear unbound 
conjugates from the chamber volume.   
4.3.3 Live Cell Imaging Chamber 
A custom live cell imaging chamber was designed and machined out of 302-grade 
stainless steel.  The system is shown in exploded form in figure 4.1. The assembly is 
comprised of three pieces: a central chamber, which contains the inlet and outlet ports, 
and two clamping pieces (upper and lower) that serve to compress the system, creating a 
water-tight chamber within.  The perfusing fluid is allowed to flow through these small 
inlet and outlet channels, which are adapted on the outside of the central chamber to be 
compatible with a general Luer-type fitting for easy connect/disconnect.  Two 40mm 
diameter coverslips (Bioptechs, Inc.) are placed in contact with the central chamber.  To 
maintain a water-tight seal, O-rings (not shown) are placed in grooves, between the 
coverslips and the central chamber.  To compress the O-rings, the top and bottom 
clamping pieces are attached to the central chamber via a set of 8 radial-symmetric 
screws on each face.  Thus, the system can be easily closed to the outside environment.  
The addition of a sterile filter in the inlet stream prevents introduction of any microbial 
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contamination. A simple peristaltic pump (not shown) can provide fluid perfusion at very 
low flow rates (less than 0.1 mL per minute). The system can also incorporate a separate 
in-line heater (not shown) to increase the temperature of the perfusing fluid to 37°C. In 
addition, a set of four, 20Ω resistors are installed onto central chamber piece, which are 
controlled via a dual channel temperature controller.  These allow the entire system to 
maintain elevated temperature for a closer approximation to in-vivo conditions.  It is 
important to note, however, that pH control is not currently implemented, although the 
volume of fluid in the chamber results in relative stability for several hours, as evidenced 















in upright scopes) 
Figure 4.1. Exploded view of the custom imaging chamber used for live cell imaging experiments.  
The assembly contains three pieces machined from 302 grade stainless steel: (1) middle chamber, 
which contains the perfusing fluid with inlet and outlet ports, and two clamps (top and bottom) that 
serve to secure two 40mm coverslips in place.  A water-tight seal is maintained by O-rings (not 
shown) placed between each coverslip and the central chamber assembly.  The top and bottom 
clamps are also beveled for easier access of objectives and/or condenser lenses.  
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4.3.4 Darkfield Imaging 
Imaging was performed using a Leica DM6000 upright microscope, equipped to 
image in brightfield (both transmitted and reflected), phase, darkfield (transmitted and 
reflected), and fluorescence modes, with an option for polarization sensitivity in all 
modes.  Images of cells at low magnification (20x), were acquired using epi-illuminated 
darkfield imaging.  In this setup, a 75W Xe light source illuminated the sample through a 
specialized Darkfield/Brightfield objective (Leica), with outer annular NA of 0.90-0.95, 
and images were collected through the inner annulus of the same objective, with a 
collection NA of 0.5.  As stated previously, the separation of illumination and collection 
light allows the detection of only higher diffraction orders, and suppresses any specular 
reflections. 
All darkfield images were acquired using a 12-bit ultra-sensitive CCD camera (Q-
imaging, Retiga EXi), equipped with an RGB automated LCD filter wheel for color 
capability.  This camera has a pixel resolution of 1360x1036, corresponding to 
approximately 3 pixels/µm, which is within the diffractin limitied regime.   
4.3.5 Transmission Electron Microscopy 
Adherent cells were cultured on sterilized discs of Aclar polymer.  After labeling, 
cells were fixed in 10% buffered formaldehyde, followed by cold 2% glutaraldehyde, and 
then dehydrated in separate ethanol and acetone series. Samples were then embedded in a 
matrix of epoxy (Embed
®
 812), and sectioned in a Leica Ultracut UCT cryotome into c. 
100nm slices.  Samples were imaged using a Philips EM 208 Transmission Electron 
Microscope. 
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Figure 4.2  Operation of the PARISS
® 
hyperspectral imaging device.  The sample is 
translated laterally under an objective, and a slit allows serial passage of thin 
“slices” of the image through to a dispersive element, which projects a 2D data set 
onto a CCD.  The y-direction contains spatial information, and the x-direction 
contains the spectral data.  A beamsplitter below the dispersion elements also allows 
conventional 2D spatial imaging of the field of view to assist in orienting the sample.   
4.3.6 PARISS Hyperspectral Imaging Device   
In order to evaluate the full spectral profile at each pixel in the darkfield images, 
hyperspectral imaging was performed on cells using a slit/dispersion system (Lightform, 
Inc. PARISS
®
), as described in section 2.6.4.  Briefly, the sample is placed on a 
computer-controlled stage which is laterally translated with precise piezo-control.  
Successive “slices” of the sample are then projected through a 25µm slit located in the 
detection path, and focused through a series of curved mirrors and a patented dispersive 
element.  This produces a two dimensional image onto a CCD chip, whereby the y-
direction contains spatial information, and the x-direction contains spectral information 
[222].  This process is repeated for each “slice” in the image.  The basic operation 











The PARISS system utilized in these studies has a spectral range of 350-850nm, 
although the optical components in the Leica Microscope, as well as the light sources 
limit practical performance to between 425 and 775nm. The spatial resolution of the 
system is determined by the optical slit in the detection path, which was set to 25µm.  At 
20x magnification, this corresponds to a pixel resolution of 1.25µm.  Current progress is 
underway to introduce a smaller slit for improved resolution, although care must be taken 
to optimize this against overall signal intensity.  The collection of scattering spectra 
requires the normalization of the acquired data with the illumination spectrum of the 
lamp.  We used either a microscopically clean electroplated aluminum mirror, imaged in 
brightfield reflected mode, or a calibrated lambertian substrate (Labsphere, Spectralon
®
), 
imaged in darkfield mode under de-focused conditions, to capture the xenon lamp 
spectra.   
4.3.7 Data Analysis 
 
Because of the three-dimensional nature of hyperspectral data, the method used for 
analysis of images becomes important.  There is no single way to visualize the sample 
imaged using this system, so a set of algorithms was developed to maximize flexibility in 
extracting various relevant information.  These were implemented in Matlab (see 
Appendix).  The aim of the algorithms in general is to reduce the dimensionality of the 
data from three to two dimensions for easier visualization.  There are three main ways to 
do this.  First, the intensity of the sample at a given wavelength can be viewed.  While 
instructive, this is mainly used to gauge the relative intensities of a sample vs. the 
background, or a labeled vs. unlabeled samples at a particular wavelength.  This 
representation is akin to simply imaging the sample with a narrow illumination bandpass 
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filter.  Conversely, the data can also be partitioned such that spectra from a particular 
pixel (or group of pixels) are displayed.  This is useful in evaluating the precise spectral 
profile of part of the sample, but clearly the loss of spatial information over the entire 
image is limiting.   
A third method used for representing the data involves creating an image of the 
sample that contains a characteristic piece of information about the spectra at each pixel.  
Most relevant to evaluating plasmon resonance coupling would be to display the extent of 
the plasmon resonance red-shift at each point in the image.  As such, an algorithm has 
been developed that identifies a peak in each pixel’s spectra (indicative of a nanoparticle 
contained within the spectra), and at what wavelength the peak occurs.  This “peak 
wavelength image” can give valuable information as to the extent of plasmon coupling 
with sub-cellular resolution. 
4.4 RESULTS 
4.4.1 Monitoring Nanoparticle Binding and Aggregation Dynamics 
EGFR over-expressing A-431 epidermoid carcinoma cells were cultured on 40mm 
diameter coverslips (Bioptechs), and placed in the imaging chamber at 25°C.  A 1:4 
mixture of contrast agents in 1x PBS and phenolphthalein-free DMEM was perfused into 
the chamber, and darkfield reflectance images were acquired at approximately 4 frames 
per minute for 40 minutes.  This supplies ample sampling to gauge the overall signal 
intensity/chromatic changes on cells (although may not be sufficient to measure the 
movements of single particles or aggregates within the cell.  Figure 4.3 indicates the 
dynamic change seen in the field of view over time as the anti-EGFR gold nanoparticles 
are allowed to bind to the adherent cells.  In (A), cells are shown immediately following 
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injection of the contrast agent – media mixture.  The signal was observed to be primarily 
blue, consistent with the natural scattering properties of cells.  Close inspection does 
reveal isolated areas of green – which may indicate some initial particle binding before 
image acquisition began.  However, in (B), images are shown 20 minutes after initial 
exposure to contrast agents, and in (C), images are shown 40 minutes after exposure.    
 
As can be seen, the scattering properties change markedly, with a progressive shift in 
the detected signal to the green spectral region.  This result was highly repeatable, 
observed in greater than 50% of cells in the field of view.  Due to the large background 
from unbound nanoparticles in solution it was necessary to subtract the background from 
each image using a rolling ball image processing algorithm to optimize signal-to-
background (which originally was 3-4).  It is interesting to note that, at least initially, 
darkfield imaging of cells does not reveal the pronounced red-shift seen in previous 
samples.  Inspection of the above images seems to suggest that the most of the particles 
are present on the cell surface.  In addition, it is apparent that the labeling dynamics are 
somewhat slower due to the fact that the cells are affixed to a surface, and not in 
suspension.  Also, the contrast agent was introduced at approximately 25% of the 
A B C 
Figure 4.3 Darkfield images of A-431 cells during the labeling process captured using the live 
imaging chamber.  In (A), the native scattering from the cells are seen immediately following 
contrast agent injection.  In (B), a significant increase in the overall green signal is seen 20 minutes 
later.  Part (C) shows a more complete labeling pattern, approximately 40 minutes after contrast 
agent application.  Images were acquired at 20x objective magnification. Scale bar is c. 10µm.    
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concentration used in the previously described studies.  However, upon longer-term 
imaging, the bound nanoparticles show a progressive red shifting, as shown in figure 4.4.  
At left (A) shows cells after labeling for 60 minutes and subsequent clearance of excess 
unbound conjugates.  Note that the scattering signal attributable to nanoparticles is green 
to yellow, consistent with images shown in figure 4.3.  At right (B), another image was 
acquired after a further 60 minutes had transpired.  The scattering signal attributable to 
nanoparticles displays a prominent red-shift over this relatively lengthy period of time.  
Cells appeared to remain healthy, as evidenced by the presence of filopodia, although 
future experiments will need to confirm cell viability more rigorously.  The red-shifting 
effect was highly reproducible, and further characterization and modulation will serve to 
elucidate the specifics of this process. 
 
A B 
Figure 4.4 Longer term aggregation of anti-EGFR gold nanoparticles.  At left, (A) shows a reflected 
darkfield image of A-431 cells, acquired after initial labeling and subsequent clearing of unbound 
conjugates from the imaging chamber.  Note the predominantly green-yellow character of the 
nanoparticle signal.  The image at right (B) shows the same field of view after an additional 60 
minutes, displaying a noticeable, longer-term red shift in the overall signal.  Scale bar is 20µm. 
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4.4.2 Transmission Electron Microscopy 
Of critical importance is determining what causes this red shift over time.  As has been 
previously described, the compartmentalization of EGFR generally follows two distinct 
aggregation steps:  First, EGFR clusters into clathrin-coated pits on the cell surface [134], 
as a precursor to the secondary step of endocytosis, and lysosomal sequestration and 
degradation [137] in a cell-cycle dependent manner.  To independently evaluate the 
nanoscale arrangement of nanoparticles within the sample, cells were grown on Aclar 
polymer discs, labeled as described, fixed and prepared for transmission electron 
microscopy (TEM).   
Figure 4.5 illustrates representative TEM images of A-431 cells labeled with anti-
EGFR contrast agents at 10
12
 particles per mL at room temperature.  At left (A), the 
plasma membrane is shown of a cell exposed to conjugates for 10-15 minutes before 
immediate washing and fixation.  The image shows that most of the nanoparticles are at 
or near the plasma membrane, and appear to be organized into mainly two-dimensional 
aggregates, as evidenced by particle “chains” seen in cryosections image projections.  In 
contrast, the image at right (B) shows the plasma membrane boundary for another A-431 
cell exposed to contrast agents for 60-70 minutes before washing and fixation.  In this 
case, nanoparticle arrangements appear to include endosomal vesicles, and are organized 
into three-dimensional aggregates, with particles lining the inner surface of the 
endosomes.  This data seem to suggest that longer-term reorganization of EGFR-bound 
nanoparticles does result in optical property shifts. 
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4.4.3 Modulating Labeling Temperature to Control Aggregation State 
To evaluate this effect under more controlled conditions, the process of endocytosis 
in labeled A-431 cells was modulated by manipulating the temperature at which cells 
were labeled.  It has been observed that endocytosis of EGFR molecules is significantly 
inhibited at 4°C, proceeds incompletely at or near room temperature, and forms mature 
lysosomal vesicles only at 37°C  [97].  As such, 3 cell samples were exposed to anti-
EGFR contrast agents (10
12
 particles per mL) for at 4°C, 25°, and 37°C, respectively, for 
60 minutes.  After this time period, cells were immediately washed in cold 1x PBS and 
fixed in 10% buffered formalin to preserve the temperature-mediated nanoparticle 
arrangement.  Additional observations may be necessary to evaluate if fixation alters the 
particle arrangement on the cells, but initially only relative changes with temperature are 
considered.  Figure 4.6 shows examples of darkfield imaging of each of these three 
A B 
Figure 4.5  Transmission Electron Microscopy (TEM) images of A-431 cells labeled with anti-
EGFR contrast agents for 10 minutes (A), and 75 minutes (B) before being immediately fixed in 
10% buffered formalin.  Note that in (A), particles are concentrated on or near the surface, 
largely in “planar” or two-dimensional aggregates.  In (B), particles are mainly concentrated in 
endocytotic vesicles in a three-dimensional aggregate.  Scale bar is 200 nm.  The author would 
like to gratefully acknowledge Nathan Harrison for sectioning and imaging of these samples. 
Scale bar is c. 500nm. 
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samples.  Single cells are shown in the field of view to emphasize the sub-cellular 
appearance and localization of the nanoparticles, but results were highly repeatable from 
cell to cell (more than 10 cells from each temperature were analyzed).  In (A), at left, a 
cell is shown that was exposed to contrast agents for 60 minutes at 4°C.  Notice that the 
signal attributable to nanoparticles is localized almost wholly to the cell periphery, and 
does not display a dramatic red shift relative to isolated particles.  In (B), however, a cell 
is shown that was exposed to conjugates for the same period of time, but at 25°C.  In this 
case, a marked scattering signal shift as well as noticeable increase in overall signal is 
observed both on the cell exterior and interior.  Finally, the image at right (C) indicates 
the overall appearance of cells labeled at 37°C.  The signal in this sample is clearly red 
shifted relative to both lower temperature samples. In addition, the particles appear 
mainly localized away from the cell periphery, and are concentrated in the areas 
surrounding the nucleus, consistent with lysosomal degradation (although confocal 
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imaging would confirm this more rigorously).  Identical results were seen in >90% of 
cells in the field of view at each temperature. 
4.4.4 Hyperspectral Imaging of Cells Labeled at Different Temperatures 
In addition to conventional RGB image capture, hyperspectral imaging, using the 
PARISS
®
 system (Lightform, Inc.), was performed on each of the samples to 
quantitatively evaluate the temperature-induced plasmon coupling trend.  Refer to section 
4.3.6 for principles of operation for this instrument.  Complete spectral profiles were 
captured of 2-3 fields of view for each temperature point, each containing 5-15 cells.  The 
data was then analyzed in a pixel-by-pixel fashion to identify peaks in each pixel’s 
spectrum.  The spectra were first filtered by using a moving average algorithm, with a 
window size of 3nm to remove high frequency noise in the signal.  Peaks were identified 
using a well-known algorithm of finding local maxima (refer to Appendix for details).  
Peaks between 515nm and 750nm were considered, to avoid noise artifacts.  If the peak 
identified was above a threshold value (set to 10% higher than the measured background 
A B C 
Figure 4.6 Darkfield imaging of A-431 cells labeled with EGFR contrast agents at 4°C (A), 25°C 
(B), and 37°C (C), each for 60 minutes.  At 4°C (A), nanoparticles appear to be localized near the 
cell membrane, and display a mainly green scattering profile.  At 25°C (B), particles appear 
yellow, with some evidence of internalization.  Finally, at 37°C (C), particles appear mainly within 
the peri-nuclear areas of the cell, and display a red shifted scattering profile relative to samples 
shown in (A) and (B).   
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scattering level), that pixel’s position is given a peak wavelength value.  If no peak was 
found within the given wavelength range, the spectrum was assumed to be essentially 
monotonically decreasing, in accordance with accepted intrinsic scattering behavior for 
cellular components [152], and given a peak scattering value of 400nm (the shortest 
reliable wavelength limit of the instrument). If a particular pixel’s spectrum did not 
exceed the threshold value, it was assumed to be background signal, and identified by a 
black (RGB = 0,0,0) pixel value.  Extensive previous testing and comparison of the 
algorithm against manual inspection of the data established its reliability.   Representative 
example peak wavelength images of single cells are shown in Figure 4.7 (A), (B), and 
(C), corresponding to cells labeled for 1 hour at 4°C, 25°C, and 37°C, respectively.  
These images indicate an increase in plasmon resonance red-shifting seen as a function of 
labeling temperature.  Also note that signals attributable to particles are mainly confined 
to the cell periphery for those cells labeled at 4°C – as the green signal is seen as a ring 
around the cell.  These signals seem to occupy most or all of the cells labeled at 25°C, 
and seem to be primarily internalized in the 37°C case – although confocal imaging or 
similar sectioning technique will prove this more conclusively.  Similar analysis was 
done for 10-20 cells from each of the three labeling temperatures, and the results were 
organized into a histogram, seen in Figure 4.7(D).  This reveals a clear shift in the peak 
wavelength distribution as a function of temperature.  Also of note is the dramatic 
increase in distribution width seen when labeling at 37°C.  A biological explanation for 
this behavior is not entirely clear, but it has been shown that the endocytosis to lysosomal 
pathway is only fully functional at 37°C [97], so the wide distribution of peak 
wavelengths may indicate a wide distribution of endosomal vesicles within the cell.  
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Quixotically, however, there seems to be a larger population of spectra with far red-
shifted spectra a 4°C than at 25°C – although this is not immediately apparent in the RGB 
images or hyperspectral images.  Future work will attempt to assign biological/physical 
meaning to this apparent inconsistency.  The average and median wavelengths are 
summarized for each temperature in Table 4.1 below, and illustrate the overall red 
shifting trend.    
 
Table 4.1  Average and median peak wavelengths for each labeling temperature. 
 
 
 Labeling Temperature 
 4°C 25°C 37°C 
Average Peak (nm) 566 573 607 
Median Peak  (nm) 551 573 585 
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Peak Wavelength (nm) 



















A B C 
D 
Figure 4.7.  Hyperspectral imaging of cells labeled at different temperatures.  Peak 
wavelength images (A-C), of representative cells are shown, labeled at 4°C, 25°C, and 
37°C, respectively.  In these images, each pixel value corresponds to the detected peak 
scattering wavelength at that pixel.  Images clearly show increased red shifting of 
plasmon resonances concomitant with increases in temperature.  Also, peaks between 
500-700nm are seen mainly on the cell periphery in (A), throughout the cell in (B) and 
mainly in the peri-nuclear areas in (C).  Scale bar is 10µm.  Histograms of 10-20 cells, 
labeled at each of the three temperatures are shown in (D).  Note the distribution shifts 
between each temperature, and also the distinct broadening of the distribution seen at 
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4.5 DISCUSSION 
It is clear from these studies and previous that immuno-targeted gold nanoparticles 
are quite sensitive to the nanoscale arrangement of the EGFR molecules to which they are 
attached.  This arrangement – in reality a dynamic rearrangement of biomolecules – and 
the resulting optical property changes opens up further possibilities for immuno-targeted 
gold nanoparticles.  On the one hand, biologically directed clustering and movement of 
EGFR-conjugate complexes can allow the imaging of in-situ molecular trafficking in real 
time with a simple optical setup. While many imaging studies to date have elucidated 
EGFR trafficking mechanisms [83, 143, 272], there is a dearth of methods that are 
sensitive to nanometer level organization in living cells.   At the same time, these 
molecular mechanisms give greater insight into the contrast enhancing potentials and 
limitations for application to clinical uses of this technology. 
As was discussed in Chapter 3, plasmon coupling is a major contributing factor for 
enhancing contrast when imaging EGFR expression in cell cultures.  However, it seems 
clear from the studies contained in this chapter that the extent of plasmon coupling is 
intricately entwined with the trafficking patterns of EGFR.  As was seen when 
monitoring the shorter-term labeling dynamics, extensive plasmon coupling does not 
occur immediately upon nanoparticle binding to the cell surface.  Even when using A431 
cells, whose EGFR expression level is greater than 10
6
 molecules per cell [274],  
extensive plasmon resonance shifting is not seen on the cell surface.  This expression 
level corresponds to an average EGFR-EGFR distance of less than 40nm – however data 
has shown that less than half of receptors are ultimately labeled (data not shown), and this 
is a highly time- and concentration-dependent process.  Rather, it it appears the 
endocytotic pathway which creates conditions for much higher order aggregation [135, 
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138, 143, 271], as well as aggregation in three dimensions, as evidenced by optical 
imaging, and more rigorously shown via TEM images.  From an electrodynamic point of 
view, this would be expected:  nanoparticles in a two-dimensional aggregate do not have 
the same number of nearest neighbors as do an equal number of equally spaced particles 
arranged in three dimensions.  Hyperspectral imaging shows quantitatively that plasmon 
red-shifting can indirectly be controlled by temperature modulation – a controller of the 
endocytosis pathway.   
From a biological and clinical point of view, the detection of EGFR dimerization and 
activation remains an attractive goal, but as the data suggests, EGFR activation and 
trafficking events are dynamic processes that serve to modulate cell regulatory 
mechanisms [271].  Future work with immuno-targeted gold nanoparticles may include 
efforts to isolate membrane vs. endocytotic aggregation more clearly via interference 
with cell cytoskeletal properties. Two-dimensional clustering has been observed in 
membrane preparations without actin or microtubule components [131]. This will aid in 
ongoing theoretical studies whereby spectral data and spatial arrangement of particles can 
be related in both a forward and backward model.  In the end, a holistic view of the 
EGFR life cycle should be attainable using metal nanoparticles.  
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Detection of EGFR Expression in Complex In-Vitro, Ex-Vivo and In-
Vivo Biological Models* 
5.1 ABSTRACT 
Results from the previous two chapters aim to identify the basic principles and 
mechanisms for establishing the feasibility of using immuno-targeted gold nanoparticles 
as molecular specific labels for EGFR over-expressing cells.  In this chapter, these results 
are expanded upon by applying the same scheme in more complex biological models.  
The approach for this work relies upon testing nanoparticle imaging in models of 
progressively increasing complexity to identify possible strategies for, and barriers 
against, eventual clinical implementation. 
We show that, with the aid of the tissue permeabilizer dimethyl sulfoxide (DMSO), 
immuno-targeted gold nanoparticles can be delivered through homogeneous and 
heterogeneous three-dimensional tissue phantoms, to a depth of at least 300µm.  The 
heterogeneous tissue phantoms serve to indicate that the contrast agents retain their 
molecular specificity in a highly dense biological environment.  Further, gold 
nanoparticle conjugates are effectively delivered in abnormal ex-vivo cervical cancer 
biopsies, although delivery was reduced to the superficial c. 100-150µm in normal 
samples, presumably due to the increased tissue permeability seen with progression of 
carcinogenesis.  Overall, we show an increased normal to abnormal signal intensity ratio 
between paired biopsy samples as the clinical grade of dysplasia worsens.  As a good 
indicator of the efficiency of nanoparticle delivery, we also show an increase in overall 
                                                 
* Contents of this chapter have been published in Cancer Res. 63, pp. 1999-2004 (2003) and J. Biomed. Opt. 13 (2007), (in press). 
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scattering in confocal images as a function of increasing depth in the epithelium – 
consistent with literature paradigms that indicate highest EGFR expression nearest the 
basal layers.  We show examples of in-vivo EGFR imaging in the hamster cheek pouch 
model of oral carcinogenesis.  Although results were not always repeatable, we 
demonstrate that a c. 10-fold increase in confocal image signal between normal and 
abnormal tissue is possible, dramatically improving on values previously reported for 
EGFR imaging in the same oral cavity model [250].  Finally, preliminary data is shown 
that indicates that gold nanoparticles may be used to identify metastatic neoplasms found 
in cervical sentinel lymph nodes in advanced cases of oral cavity cancer.  EGFR over-
expressing cells were detected using confocal reflectance microscopy in a test case of 
metastatic oral cavity carcinoma, and confirmed by pathological diagnosis.  This opens 
new avenues for medical applications of immuno-targeted gold nanoparticles.   
5.2 INTRODUCTION 
The in-vivo molecular characterization of disease, especially cancer, remains a critical 
task in bringing to fruition the concept of “individualized medicine” [275].  Determining 
key elements of a patient’s genetic and proteomic profile, especially in abnormal tissues, 
holds the promise of vastly improved treatment regimens and better overall patient 
outcome. While a multitude of comprehensive strategies are being explored, the 
utilization of nanomaterials in conjunction with optical imaging is proving to be a 
powerful approach [245, 264, 276-280].  This generalized strategy relies on four basic 
components:  (1) optically active nanomaterials, (2) cheap, portable, three-dimensional, 
real-time imaging tools, (3) effective targeting and delivering capability and (4) realistic, 
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reproducible, and highly characterized biological models in which to test various 
approaches.  Figure 5.1 graphically illustrates this multi-component approach.  
 
Figure 5.1 Conceptual approach to development of non-invasive molecular imaging of epithelial 
carcinogenesis is based on synergy of: optically active gold nanoparticles; cancer specific probe 
molecules; real-time optical imaging; and topical delivery formulations. 
  
Numerous varieties of optically active nanomaterials have already been described in 
the case of quantum dots (qdots) [22-24, 82, 83, 180, 181] and plasmonic particles [30, 
32, 63, 70, 71, 242, 281], and demonstrate the intense interest in development and 
application of mesoscopic materials for molecular-based bioimaging applications. While 
utilizing different mechanisms for signal generation, both qdots and plasmonic 
nanoparticles can be used to produce high-quality molecular-specific information in real 













microscopic techniques to image living tissue with sub-cellular resolution.  Vital 
microscopies, such as optical coherence tomography (OCT) and reflectance confocal 
microscopy (RCM) image reflected light, thereby providing a detailed three-dimensional 
picture of tissue microanatomy without the need for physical sectioning [53, 145].  These 
technologies provide excellent spatial resolution (1 - 10 microns) with penetration depth 
ranging from 300 microns to 1-2 mm, depending on tissue composition, illumination 
wavelength, and detection scheme.  These systems are portable and inexpensive 
compared to other high resolution imaging technologies such as MRI or micro-CT; as 
such they are well-suited for early screening and diagnosis of superficial disease. By 
themselves, however, OCT and RCM mainly provide images of tissue microanatomy, 
and their ability to image molecular changes associated with carcinogenesis is limited.   
In an effort to develop a means for molecular specificity to be used in in-vivo 
reflected light microscopy (such as OCT and RCM), this chapter demonstrates the use of 
gold nanoparticles targeted to EGFR and applied in several biological models of pre-
cancer and cancer. As noted previously, gold nanoparticles have been extensively used as 
molecular specific stains in electron microscopy [68, 282].  As result, the fundamental 
principles of interactions between gold particles and biomolecules have been thoroughly 
studied.  Using this knowledge, as well as results and principles developed from the 
previous two chapters, the application of immuno-targeted gold nanoparticles is 
presented and discussed.  We demonstrate the application of gold bioconjugates in 
several biologically relevant models of cancer with increasing complexity.  
Homogeneous and heterogeneous engineered tissue constructs, three-dimensional cell 
cultures that mimic major features of epithelial tissue [283, 284], were explored.  We 
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prepared engineered tissue constructs consisting of densely packed, multiple layers of 
EGFR-positive and negative cells atop a collagen stroma.  Following this, we show the 
application of contrast agents in normal and neoplastic fresh ex-vivo cervical biopsies, 
subcutaneously injected tumors in an immuno-deficient mouse model, human cervical 
lymph nodes of the head and neck as well as an in-vivo hamster check pouch model.   
5.3 MATERIALS AND METHODS 
5.3.1 Anti-EGFR Contrast Agents 
25 nm gold nanoparticles were synthesized via sodium citrate reduction of gold 
tetrachloride (Sigma), as described in [201]. The conjugates of gold nanoparticles with 
anti-EGFR monoclonal antibodies were prepared using the method that was originally 
developed for preparation of gold immunostains for electron microscopy (18, 19). 
Briefly, 0.1 mg/mL of anti-EGFR antibodies (clone 225, Neomarkers or clone 29.1, 
Sigma), in a 40 mM HEPES buffer, pH 7.4, were mixed for 20-30 minutes with an equal 
volume of gold nanoparticles at approximately 10
12 
particles per mL.  Conjugates were 
centrifuged at 3000 x rcf for 1-1.5 hours in the presence of 1% PEG and re-suspended at 
ca. 2 x 10
12 
particle concentration in a PBS buffer, pH 7.4 containing 1% BSA and 0.2% 
PEG. Bifunctional contrast agents were synthesized via a monoclonal antibody labeling 
kit (Molecular Probes) to attach fluorescein or Alexa Fluor 647 dye to purified antibodies 
via a succinimidyl ester reaction that forms linkages between the dye and primary amines 
on the antibody. Then, fluorescently labeled antibodies were conjugated with gold 




5.3.2 Cell Cultures 
Cells were cultured in Dulbecco’s Modified Eagle Media (DMEM) (SiHa, MDA-
MB-435) or MEM (MDA-MB-468) plus 10% FBS and grown at 37ºC in 5% CO2.  Cells 
were harvested via exposure to EDTA-trypsin for 5-10 minutes at 37°C, collected, 
centrifuged at c. 200 x rcf for 3-5 minutes, aspirated, and re-suspended in 
phenolphthalein-free media before imaging so as to reduce optical absorption artifacts.   
5.3.3 Preparation of Three Dimensional Epithelial Tissue Constructs   
For the homogeneous epithelial tissue constructs (tissue phantoms), SiHa cervical 
cancer cells were harvested as described and re-suspended in a 1mg/mL buffered (pH 
7.4) collagen solution (Roche) at a concentration of approximately 80-100x10
6
 cells per 
mL. A 200-500µm thick disk of the cell/collagen mixture was coated onto a permeable 
membrane 24-well insert (Transwell, Corning) and left to proliferate overnight in the 
incubator [284]. For the heterogeneous tissue phantoms, MDA-MB-468 and MDA-MB-
435 cells were first cultured, harvested, and incubated with membrane permeable 
derivatives of fluorescein and seminaphthorhodafluors (SNARF) (Molecular Probes, 
Invitrogen), respectively, in DMEM for 1 hour and washed.  The dyes serve to 
independently confirm each cell’s identity..  The dyes are rendered membrane permeable 
via a chloromethyl group that is enzymatically cleaved upon entering a viable cell.  Thus, 
once in the cytosol, the dye becomes membrane impermeable, and does not exit the cell. 
These two cell lines were chosen due to their similarity in organ site and morphology, but 
extreme difference in EGFR expression level A 1:1 (v/v) mixture of the two cell lines 
was suspended in a collagen solution as described above, and the phantom was prepared 
as before. In general, phantoms were topically exposed to 100µL of contrast agents (at 
ca. 10
12
 particles per mL) in a 1x PBS solution containing 10% DMSO for 30 minutes, 
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briefly washed in media, and transversely sectioned using a Krumdieck slicer before 
imaging. 
5.3.4 Balb/c Nude Mouse Model 
Adapting the protocol in [285], immuno-deficient Balb/c nude mice were anesthetized in 
ketamine, and intraperitoneally injected with approximately 2 aliquots of 0.1 mL of a 
suspension of SiHa cells in matrigel (BD Biosciences) at a concentration of c. 10
6
 
cells/mL in both sides of the mammary fat pad..   Mice were then housed for up to 6 
weeks while tumors proliferated.  When tumors reached a nominal diameter of 
approximately 5mm, mice were sacrificed via ketamine overdose and cervical dislocation 
and a skin flap was exposed in the mammary fat pad to reveal both tumors, and tumors 
were surgically removed. One tumor was placed in a solution of 25nm gold nanoparticles 
conjugated to anti-EGFR monoclonal antibodies (clone 29.1.1, Sigma) which were 
suspended in a 10% DMSO in 1x PBS solution for 45 minutes at room temperature.  The 
other, control tumor, was placed in a 10% DMSO in 1x PBS solution only, and then both 
were imaged.     
5.3.5 Human Cervical Biopsies 
Clinically normal and abnormal cervical biopsies were obtained from consenting 
women seen at the Department of Gynecologic Oncology, M.D. Anderson Cancer 
Center. Biopsies were placed in chilled DMEM and later embedded in a 3% agarose gel 
such that only the epithelial surface was exposed. 200µL of contrast agents (at ca. 10
12
 
particles per mL) in 1x PBS containing 10% DMSO (v/v) were applied to the surface for 
45 minutes at room temperature. Then, biopsies were transversely sectioned and imaged. 
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After imaging, samples were placed in 10% formalin and submitted for histological 
evaluation. 
5.3.6 Hamster Cheek Pouch Model 
The Hamster check pouch model remains a well characterized model of oral cavity 
carcinogenesis [286]. 10 Golden Syrian Hamsters were treated 2-3 times weekly with a 
0.5% solution of dimethyl benz(α)anthracene (DMBA) in mineral oil on the right 
mucosal side of the cheek pouch under the supervision of a small animal veterinarian. 
Two non-treated, separately housed animals functioned as normal controls. After 
anesthetization with ketamine, the cheek pouch was inverted and 200-400µL of contrast 
agent (at ca. 10
12
 particles per mL) was applied topically in 1x PBS containing 10% 
DMSO (v/v) for 15-20 minutes.  Contrast agent exposure times were shorter than those 
used for biopsies due to the relatively short anesthetization times that are safely attained 
used ketamine. After washing, the hamsters were imaged using a portable reflectance 
confocal microscope [149]. Immediately following, biopsies were taken from the imaged 
area of the cheek pouch, and submitted for histological analysis. All animals were treated 
under the guidance from the institutionally-approved IACUC protocol study standards. 
5.3.7 Ex-Vivo Lymph Node Biopsies 
A patient seen at the M.D. Anderson Cancer Center Head and Neck Clinic who was 
scheduled for surgical resection of oral cavity carcinoma(s) and lymph node dissection 
was consensually recruited into an institutionally-sponsored patient protocol.  The tumor, 
surrounding epithelial tissue, as well as the associated lymph nodes were removed by a 
head and neck surgeon.  Care was taken during surgery to preserve the integrity of the 
tumor and associated lymphatic tissues, ensuring that the lymphatic drainage remained 
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unaffected.  1mL EGFR specific conjugates (using anti-EGFR mAb clone 225), at 10
12
 
particles per mL in 10% DMSO in 1x PBS were injected into the primary tumor site and 
allowed to drain through the lymphatic ducts into the cervical lymph node basins.  Then, 
a board-certified pathologist palpated each lymph node to determine the presence of 
metastatic growth. Both clinically normal and abnormal lymph nodes were taken for 
analysis, sectioned in the Krumdieck slicer, and imaged. 
5.3.8 Optical Imaging 
Homogeneous and heterogeneous tissue phantoms, as well as lymph node biopsies 
were imaged using a Leica TCS-4D confocal microscope using 488 nm excitation and 
515/10 nm band pass filter and 514 nm excitation for the Fluorescein-labeled cells, as 
well as to collect autofluorescence of non-tagged samples.  A 660 nm long pass filter was 
used to detect SNARF-labeled cells. Reflectance was acquired with 647 nm excitation. 
Balb/c nude mouse tumors were imaged using a Vivascope 2000 (Lucid, Inc.) portable 
laser scanning reflectance confocal microscope, with diode illumination at 830nm. 
Cervical biopsies were imaged using a Leica SP2 AOBS confocal microscope. 
Reflectance images were obtained with 594 nm and 633 nm illumination. Imaging of 
hamsters in vivo was carried out using a portable reflectance confocal microscope which 
is described in [149], and uses an 810nm diode illumination source. 
5.4 RESULTS 
5.4.1 Three-Dimensional Tissue Phantoms 
In vivo molecular imaging requires development of efficient delivery systems of 
contrast agents to their targets.  We used dimethyl sulfoxide (DMSO) to promote topical 
delivery of anti-EGFR gold conjugates. DMSO was chosen because of its permeation 
 86 
efficiency, high aqueous solubility and because it is already FDA approved for human 
use [287] in certain applications. 
We fabricated two types of 3D tissue constructs:  (1) Homogeneous phantoms 
containing a high density of SiHa cervical cells and (2) heterogeneous constructs which 
consisted of a high-density mixture of EGFR(+) MDA-MB-468 and EGFR(-) MDA-MB-
435 breast cancer cells in a 1:1 ratio. In the homogeneous case, phantoms were fabricated 
in transwell inserts (Corning), as described using SiHa cancer cells.  Phantoms were 
labeled with anti-EGFR contrast agents in either a 10% DMSO in 1x PBS solution, or in 
1x PBS only.  They were subsequently removed and transversely sliced using a 
Krumdieck slicer.  Figure 5.2A and B show transmitted and reflectance confocal images, 
respectively, of a transversely sectioned phantom labeled with the aid of DMSO.  Note 
the presence of scattering signal (with a pixel count above the nose floor of 25) 
throughout the c. 400µm thickness of the slice.  Figures 5.2C and D, however, show 
confocal transmittance and reflectance images, respectively, after an identical phantom is 
labeled without the use of DMSO as a delivery enhancing agent.  Note that labeling is 
only apparent in a thin layer on one side of the phantom.  An arrow indicates the surface 
from which contrast agents were applied.  Figure 5E includes a higher magnification 
transmitted image of the homogeneous phantom, and indicates the high density 
appearance of cell growth attainable in this model. 
In the heterogeneous case, EGFR(+) and EGFR(-) cell lines were labeled with 
membrane permeable derivatives of fluorescein and seminaphthorhodafluors (SNARF), 
respectively, which fluoresce only when they are inside the cells, as shown in low 
magnification in Figure 5.3A.  
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Note the relatively random distribution of each cell type within the phantom.  Some 
yellow signal is seen in the orange cells, and was deemed to be due to contributions from 
autofluorescence (and not dye cross-contamination). Figure 5.3B shows transverse 
sections of topically labeled heterogeneous tissue phantoms which indicate that the 




Figure 5.2 Transmittance (A, C, and E) and confocal reflectance (B and D) images of engineered 
tissue constructs labeled with anti-EGFR/gold conjugates.  The contrast agents were added on top 
(indicated by arrows) of the tissue phantoms in 10%dimethyl sulfoxide (DMSO) solution in PBS 
(A and B) or in pure PBS (C and D).  Phantoms were transversely sliced and imaged with a 
reflectance confocal microscope. Note the increased depth of penetration when using DMSO. 
Imaging at higher magnification (40X) shows the high density of the epithelial cells in the phantom 
(E).  Reflectance images were obtained with 647 nm excitation.    Arrows show the surfaces 
exposed to the contrast agents.  The scale bars are ca. 200 µm (A-D) and ca. 20 µm (E). 
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to no reflectance signal is associated with red EGFR(-) cells, and in fact the average 
signal ratio between expressing and non-expressing cells was found to be c. 10.  These 
results were repeated twice, and demonstrate that DMSO-mediated delivery does not 
adversely alter molecular specificity of the contrast agents and enables penetration 
through a thickness that corresponds to a typical epithelial layer.  
 
5.4.2 Balb/c Nude Mouse Model 
While 3D tissue constructs represent an easily reproducible in-vitro biological model, 
the cell density of these phantoms is not quite as high as is achieved in an in-vivo system.  
The Balb/c nude mouse model represents another highly reproducible model of 
carcinogenesis whereby one or more tumors are created within the subcutaneous space 
within immuno-deficient, athymic mice [288].  In this model, multiple tumors are easily 
producible in one or more regions of the subcutaneous space, thereby providing for easy 
internal controls.   After 1-6 weeks of tumor growth, the mice were sacrificed, tumors 
A B 
Figure 5.3 Heterogeneous three-dimensional tissue cultures.  (A) Low magnification 
fluorescence confocal image of a transverse section, showing distribution of EGFR(+) cells in 
green and EGFR(-) cells in red.  (B) High magnification image of the area indicated showing 
overlay of fluorescence image with corresponding reflectance image.  Reflectance signal is 
shown in white.  Scale bars are ca. 50 µm (A) and ca. 15 µm (B). 
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resected, and placed in a solution of anti-EGFR gold conjugates in 10% DMSO in 1x 
PBS for up to 45 minutes at room temperature.   The tumor was then sliced with a 
scalpel, exposing the inner necrotic core and imaged using the Vivascope portable 
confocal microscope.  Figure 5.4 summarizes the results of this experiment.  At left, 
(Figure 5.4A), a confocal reflectance image is shown of a labeled mouse tumor.  At right 
(Figure 5.4B), a similar image is shown of an un-labeled tumor.  Note that while there is 
significant signal present in both images, the labeled sample displays clear cell-
membrane type morphology in the image.  This is clearly consistent with labeling EGFR 
– a membrane-bound protein.   
 
Figure 5.4.  Confocal images (taken at 830nm) of subcutaneous tumors introduced into Balb/c nude 
mice.   At left (A), the outline of the xenograft epithelial cells are clearly present, consistent with 
EGFR labeled cells.  At right, (B), no such morphology is apparent, although a diffuse background is 
clearly present.     
 
The presence of significant signal from the unlabeled sample, however, is troubling.  
We believe that the primary reason for this relatively poor contrast (in comparison with 






within the tumor, although this remains to be confirmed.  After excision of the tumors, a 
hard layer of fibrous tissue was found to surround and permeate the tumors.  This fibrous 
component is further supported by the fact that while vascularization of the tumor was 
evident surrounding the tumor, no blood vessels were found inside the core, producing a 
necrotic zone in the middle of the tumor.  A second factor may be the illumination source 
in the Lucid Vivascope, which operates at 830nm – significantly removed from the 
optimal range for nanoparticles in the 600-650nm.   From these limited observations, we 
conclude that, while potentially useful, the athymic mouse model may have some 
limitations in use for molecular imaging studies that render tumors whose morphology is 
significantly different than those seen in pre-cancerous and early cancerous lesions in 
stratified human epithelia.   
5.4.3 Ex-Vivo Human Cervical Tissue 
While 3D tissue cultures and ectopic animal tumors remain a useful, reproducible 
pre-clinical tool, the use of human ex-vivo epithelial tissue represents a more realistic 
model. We analyzed a total of four colposcopically normal/abnormal biopsy pairs.  Table 
5.1 summarizes the histopathologic diagnoses and the abnormal to normal reflectance 
intensity ratios of images of epithelial cells after labeling. The reflectance intensity was 
integrated over the entire epithelial thickness. The histopathologic diagnoses range from 
changes associated with human papillomavirus infection to CIN 3, and represents several 
important steps in the progression of pre-cancerous changes in the cervix. The reflectance 
intensity ratio increases with progression of carcinogenesis (Table 5.1); this correlates 
well with the increase of overall EGFR expression throughout the epithelial lining  seen 
in pre-cancer progression in the cervix [102]. 
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Table 5.1. The average signal intensity ratios between abnormal and normal biopsies 
from four different pairs. Note that the abnormal/normal signal ratio increase with 
pathological severity.   
 
 
Figures 5.5A and B show representative confocal reflectance images of a biopsy with 
severe dysplasia (CIN 3), and a paired normal biopsy respectively, each labeled with anti-
EGFR gold contrast agents. The abnormal specimen clearly shows a distinct 
“honeycomb” structure characteristic of EGFR labeling on cellular membranes. No 
distinct structures are visible in the normal biopsy. We observed signal intensity 
differences of up to 21 fold between normal and abnormal cases. Figures 5.5C and D 
show the corresponding H&E staining of the abnormal and normal biopsies, respectively, 
which corroborate the clinical diagnosis with a reading from a trained pathologist.   
As further corroboration that the image morphology seen in figure 5.5 is indicative of 
EGFR expression, the relative signal strength as a function of depth below the epithelial 
surface was calculated for 10 different abnormal sites within each abnormal biopsy, and 
the average profile plotted in figure 5.6 (blue line).  Alongside this data are plotted 
findings from the literature (green dots) [102], which show a similar overall  increase.  
The data plotted in the blue line represents 10 measurements taken from different points 
in images of the case shown in figure 5.5 that was deemed by a pathologist to contain 
CIN III. 
Histopathology of 
the abnormal sample 
Reflectance intensity ratio of abnormal 
to normal samples after labeling with anti-




CIN 1 4.2 
CIN 2 11.6 
CIN 3 21 
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Figure 5.5.  Confocal reflectance images of transverse sections of abnormal (A) and normal (B) 
cervical biopsies labeled with anti-EGFR gold conjugates.  The image of the abnormal biopsy was 
obtained just above the basement membrane.  Images of tissue intrinsic fluorescence were also 
collected (not shown) to independently confirm the presence of epithelial cells in the same field of 
view.  Corresponding H&E staining of the abnormal (C) and normal (D) biopsies.  Excitation 
































Figure 5.6. Relative signal strength measured in abnormal biopsies (averaged over 10 sites) as a 
function of depth below the surface (blue line).  Note the overall increase in signal as a function of 
tissue thickness, consistent with values found in the literature.   
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Further, treatment of biopsies with non-specific contrast agents resulted in no 
apparent signal.  A remaining question, however, concerns the effect on nanoparticle 
delivery of the naturally occurring permeability increases due to the decrease in cell to 
cell junctions seen in dysplastic tissue [289].  To begin to address this, an 
abnormal/normal cervical biopsy pair was labeled fluorescently-tagged gold nanoparticle 
conjugates.  Subsequent fluorescence imaging revealed that while delivery through the 
abnormal biopsy extended past 300µm, penetration of only 100-150µm was seen with in 
the normal biopsy.  Further spectroscopic analysis (using a ball lens probe, described in 
[148], data not shown) revealed that 40% less conjugate was delivered overall to the 
normal sample.  This result seems to suggest that the carcinogenesis actually promotes 
the delivery of gold nanoparticle conjugates, though the extent of this result is better 
evaluated through a more careful study. 
5.4.4 Hamster Cheek Pouch Model 
We also demonstrated the efficacy of molecular specific imaging with gold 
bioconjugates in vivo in the hamster cheek pouch carcinogenesis model. Histologically, 
the 16-week treatment with dimethyl benz[α]anthracene (DMBA) pushes the epithelial 
lining of the cheek pouch through progressive dysplastic changes and ultimately 
carcinoma in-situ [286]. Anesthetized hamsters were imaged with a portable reflectance 
confocal microscope described in [149] right before and after topical application of anti-
EGFR gold nanoparticles. Figure 5.7 shows results of in vivo imaging of the cheek pouch 
of the same hamster at different points of the study. Images in Figure 5.7A were obtained 
before the beginning of treatment with DMBA and images in Figure 5.7B shows the 
results after 3 weeks of treatment with the carcinogen. Images on the left indicate before 
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application of contrast agents, while those on the right are taken after 30 minutes of 
application. Although the contrast agents were applied in both imaging sessions (before 
and after initiation of carcinogenesis), cell-membrane morphology characteristic for 
labeling of EGF receptors and a significant increase in scattering intensity after the 
application of gold bioconjugates were observed only after the animal was treated with 
DMBA (Figure 5.7B right). The contrast in the images between the normal animal 
(Figure 5.7A right) and the animal with early neoplastic changes (Figure 5.7B right) after 
the application of the contrast agents exceeds 10 times. Figures 5.7A and B at left 
indicate appearance before application of contrast agents.  Figure 5.7C shows that 
imaging results were confirmed using EGFR immuno-histochemical staining of cheek 
pouch biopsies taken from the areas which were imaged in vivo.  Figure 5.7C, left shows 
normal tissue, and abnormal tissue is shown in 5.7C, right. These results suggest the 
possibility of molecular specific imaging with topically delivered gold bioconjugates. 
However, they were not always repeatable. We attribute the difficulty in topical delivery 
of the nanoparticles to extremely high levels of superficial keratin expressed in the 
hamster buccal mucosa.  
The thick layer of keratin represents a significant barrier against topical delivery of 
not only nanoparticles and macromolecules but even small molecules like acetic acid. 
Fortunately, such elevated levels of surface keratin are not characteristic for human 
epithelial tissues, save for extremely advanced cases of keratosis. Therefore, future pre-
clinical evaluation of topical delivery of contrast agents should be focused on animal 























5.4.5 Resected Human Head and Neck Lymph Nodes 
While the previous results have shown that optical interrogation of immuno-




Figure 5.7. In vivo confocal reflectance imaging of EGFR overexpression in a hamster 
model.  Images shown are obtained from the same hamster before the beginning of the 
treatment with carcinogen – DMBA (A) and after 3 weeks of DMBA treatment (B).  The 
images were taken immediately before (A, left and B, left) and after (A, right and B, 
right) topical application of the anti-EGFR gold conjugates. EGFR immuno-
histochemical staining (C) reveals elevated EGFR levels in the DMBA-treated animal 
(C, right) and very low levels of EGFR expression before DMBA treatment (C, left).  
The scale bars are ca. 50 µm. 
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certainly remains other vital clinical needs for this type of molecular imaging.  It is 
particularly important to be able to stage more advanced cases in terms of the degree of 
metastatic spread that often occurs through the lymphatic system.  There is a plethora of 
current work focused on developing better lymph node metastasis detection in the breast 
[290], lung [291], and oral cavity [292], among others.  The use of optical techniques for 
“sentinel lymph node” detection – that is, detection of small metastases in the primary 
draining lymph node for a particular tumor – has become quite popular [61, 293-296], 
particularly via the use of fluorescent tracers.  To better understand the anatomy in 
question, refer to figure 5.8 from [297] which shows the relatively complex anatomy of 
the head and neck lymphatic system.  As such, this organ site in particular would benefit 
from a method that could accurately detect metastatic spread to a particular node among 
the many surrounding the oral cavity. 
To determine the feasibility of using immuno-targeted nanoparticles for micro-
metastasis detection, a patient undergoing radical dissection of an advanced oral cavity 
tumor and associated lymph nodes at the U.T. M.D. Anderson Cancer Center Head and 
Neck Clinic was enrolled in a patient protocol.  The terms of the protocol were such that 
during the surgical procedure, the tumor was resected, along with the associated 
lymphatics attached.  The sample was brought to a dedicated pathology suite where the 
primary tumor was injected with a solution of EGFR-targeted (clone 225, Neomarkers) 
gold nanoparticles suspended in a solution of 1x PBS plus 10% DMSO.  Clone 225 is 
often used for in-vivo applications, due to its being humanized [298].  A total of 2-3mL 
was injected into several positions on the tumor.  After 45-60 minutes, a board-certified 
pathologist palpated the individual lymph nodes within the sample to determine the 
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presence of metastases.  The clinically abnormal lymph nodes, along with clinically 
normal nodes were taken for imaging using the Leica TCS-4D confocal microscope.   
 
Figure 5.8.  Anatomy of human cervical lymph nodes.  Note that depending on where in the oral 
cavity a tumor arises, the primary draining lymph node (i.e. the “sentinel” lymph node) will be 
different.   
 
Figure 5.9 shows the results from imaging a clinically normal and abnormal lymph 
node from the above mentioned patient.  In (A), the confocal reflectance at 647nm is 
shown for the abnormal, while in (B) it is shown for the normal.  Immediately obvious is 
the overall increase in scattering seen in the abnormal image.  However, to more 
convincingly postulate that this is due to the presence of EGFR expressing cells within 
the lymph node, a confocal image was also taken of the same fields of view in 
fluorescence mode, under 488nm excitation and 500nm long-pass emission.  This 
excitation/emission pair is well suited to imaging the autofluorescence in cells due to 
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NADH [164], and is a good way to determine the morphological state and relative 
position of cells in a field of view.  These images are shown in figure 5.9(C) and (D) for 
the abnormal and normal, respectively.  Note that cells are discernable above the 
background level in the abnormal case, but not in the abnormal case.  Finally, in (E) and 
(F), the reflectance and fluorescence images are overlaid to give a more complete picture 
of the sample. Figure 5.9(E) shows the characteristic cell periphery morphology under 
reflectance imaging, with a bright cytoplasmic autofluorescence overlaid.  This 
morphology is highly consistent with the presence of EGFR over-expressing cells within 
the lymph node matrix.  No such morphology is seen in (F).  Both of these results were 
confirmed with conventional H&E staining of the same samples, which tested positive 
for metastasis in the abnormal node, and an absence in the normal node. While these 
results are encouraging, they are also preliminary, and certainly a more thorough study 
will be necessary to more fully explore the use of immuno-targeted gold nanoparticles for 
this application.  
5.5 DISCUSSION 
We believe that the data summarized in this chapter serves as a beginning point in 
order to posit the potential advantages and challenges of implementation of gold 
nanoparticles in the clinic. From a toxicological point of view, it is attractive that the 
bioreactivity and toxicity of metallic gold has long been established as low, as evidenced 
by the use of metallic gold implants, the exploration of gold nanoparticles as gene 
therapy carriers for HIV patients with up to 500 mg of gold applied during treatment 
[66]; and pre-clinical studies of a new minimally invasive thermal treatment of cancer 






















However, it is important to note that metallic gold is not metabolized. In some cases a 
premalignant lesion can require a long patient follow up, therefore potential interference 
between the initial labeling with gold nanoparticles and subsequent imaging should be 
Figure 5.9.  Imaging of clinically abnormal (left column) and clinically normal (right column) lymph 
nodes in resected human tissue after injection of anti-EGFR contrast agents into the primary tumor.  
First row (A & B):  confocal reflectance.  Second row (C & D):  auto-fluorescence.  Third row (E & 





considered. It is well known that EGFR is regularly internalized and degraded within the 
cell [299]. The degraded receptors are replaced with newly synthesized EGFR that can be 
targeted by the contrast agents.   The fate of the gold nanoparticles internalized is unclear, 
although uptake by macrophages has been observed in-vitro with no cytotoxic effects 
[65]. 
Delivery of nanoparticulates through mucosal boundaries has been demonstrated in a 
number of studies for a variety of size ranges. For example, 150-300 nm diameter 
chitosan derivative-based nanoparticles have been successfully used as therapeutic 
carriers for peanut allergy immunization in the intestinal epithelium [300].  DMSO has 
been shown to facilitate trans-mucosal transport of several materials such as antibodies 
[301], anti-cancer drugs [302], and photosensitizers [303].  The FDA has approved 
DMSO as a treatment for interstitial cystitis via bladder instillation [287], and the toxicity 
of DMSO has been shown to be quite low, with an LD50 of 17,400 mg/kg.  Further, there 
are several other compounds that have been shown to promote transmucosal permeability 
such as polyvinyl pyrrolidone (PVP) [304], chitosan [300], and lipid surfactants [305] 
that may be utilized for promoting topical delivery of gold nanoparticle contrast agents.  
From an imaging point of view, it is clear that gold nanoparticles can produce high 
quality, molecular specific images under many circumstances. The abnormal to normal 
signal intensity ratio was shown far higher than the actual level of EGFR over-expression 
in both the cervical biopsy and the in-vivo hamster cheek pouch. There are, however, 
challenges as well, including the presence of high endogenous scattering sources, such as 
keratin, which also act as a transport barrier to both photons and nanoparticles.  As was 
mentioned, the delivery of nanoparticles was found to be significantly reduced in a 
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normal cervical biopsy.  While this may be viewed advantageously, it would certainly be 
worthwhile to study further the effect of carcinogenesis-enabled tissue permeability, and 
tight junction reduction as a facilitator of contrast agent delivery.  The preceding data 
will, hopefully, act as a guide for a number of future studies.   
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Magnetic Gold Multimodal Nanoparticles for EGFR Imaging* 
6.1 ABSTRACT 
It has been shown that molecular specific labeling of EGFR is possible in a range of 
increasingly complex biological models, often with quite high contrast.  However, a 
multifaceted approach is clearly needed in many instances to increase the signal strength 
and specificity in cases where optimal delivery of contrast agents is difficult, or if there is 
a high concentration of endogenous scatterers.  This chapter details a novel approach for 
optical imaging that combines the advantages of molecularly targeted plasmonic 
nanoparticles and harmonic magnetic actuation.  This combination is achieved through 
hybrid nanoparticles with an iron oxide core surrounded by a gold layer. The 
nanoparticles are targeted in-vitro to epidermal growth factor receptor, a common cancer 
biomarker. The gold portion resonantly scatters visible light giving a strong optical signal 
and the superparamagnetic core provides a means to externally modulate the optical 
signal. The combination of bright plasmon resonance scattering and magnetic actuation 
produces a dramatic increase in contrast in optical imaging of cells labeled with hybrid 
gold/iron oxide nanoparticles. 
6.2 INTRODUCTION 
Exogenous contrast agents are widely used to increase signal intensity and specificity 
during optical interrogation of biological materials.  Organic fluorescent dyes are 
traditional contrast enhancing molecules for in vitro and in vivo optical imaging [167-
                                                 
* The contents of this chapter have been published in Opt. Exp. 14(26) 12930-12943 
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170].  Recent advances in nanotechnology have led to the development of novel bright 
contrast agents, including quantum dots [23, 60, 180-182] and plasmonic nanoparticles 
[30, 70, 81, 195, 244, 245].  Progress in nanomaterial chemistry has allowed synthesis of 
semiconductor quantum dots with increased fluorescence efficiencies [306], tunable 
emission bands [56], and relatively slow photobleaching rates [23].  On the other hand, it 
was demonstrated that plasmonic metal nanoparticles offer additional advantages over 
luminescent quantum dots including significantly larger optical cross sections, complete 
resistance to photobleaching, and non-toxic constituent materials [30, 70, 81, 195, 244, 
245, 265].   
Strategies using antibody or aptamer targeting molecules provide molecular 
specificity to optical imaging [307, 308]. However, most biological systems are very 
complex both in composition and morphology. Thus, endogenous scatterers and 
fluorophors can account for a significant portion of the total signal intensity causing 
problems in molecular specific optical imaging, especially in vivo [180]. Molecular 
specific contrast agents would be better utilized if novel optical methods were employed 
that concurrently reduce or prevent unwanted background signal.  It was demonstrated 
that contribution of the endogenous background signal can be reduced using the effect of 
plasmon resonance coupling between gold nanoparticles [195, 245].  The dipole-dipole 
coupling between closely spaced gold particles produces a red wavelength shift in their 
scattering and extinction cross sections [191, 309].  This property was exploited for 
development of ultrasensitive DNA assays in vitro [71, 310, 311].  Recently, we used 12 
nm gold nanoparticles conjugated to monoclonal antibodies specific for epidermal growth 
factor receptor (EGFR) to label living cancer cells [195].  Although isolated nanoparticles 
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have a maximum scattering cross section in the green optical region, labeled cells exhibit 
a very strong scattering signal in the red.  This red-shift behavior was attributed to the 
dipole-dipole coupling of gold bioconjugates bound to EGFR molecules on the cell 
surface [195].  The effect of plasmon resonance coupling affords an opportunity to 
spectrally reject the background associated with endogenous cellular scattering which is 
predominant in the blue spectral region.   
Another effective strategy to reduce unwanted background signal has been 
demonstrated by Oldenburg, et al. [312] in optical coherence tomography (OCT) imaging 
of macrophages loaded with magnetic particles.  The approach is based on inducing a 
magnetically actuated movement in cells containing magnetic iron oxide microparticles. 
Subsequent implementation of a simple frame subtraction algorithm reduces the 
background signal associated with the surrounding non-magnetic media.  A similar 
approach was used by Anker et al. [313].  Polystyrene microbeads loaded with a dye and 
a ferromagnetic material were sputter-coated with aluminum or gold leaving a small 
uncoated area on the surface of the beads.  Then, the microbeads were used for optical 
imaging and exhibited a bright fluorescence signal only when they were magnetically 
oriented with a metal coated side facing away from a detector.  The metal coating 
blocked the fluorescent emission when the metal-coated side was oriented towards the 
detector, and image subtraction removed non-specific signals.  In another study, 
superparamagnetic iron oxide nanoparticles (SPIO) have been magnetically actuated in 
mouse liver tissue and detected using ultrasound imaging [314].   
Recently, a new type of nanomaterial - magnetic/gold composite nanoparticles have 
been synthesized by several different routes [64, 237, 315].  Lin et al. [315] utilized an 
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inverse micelle technique to form crystalline iron cores within micelles and subsequently 
adding chlorauric acid and sodium borohydride to obtain gold-coated iron.  The inverse 
micelle technique creates particles with a narrow size distribution, but further steps must 
be taken to transfer them to aqueous solution for subsequent functionalization.  The 
magnetic properties of these particles were further characterized in [316].  It is important 
to note that the gold coating does not prevent the iron core from oxidizing over a period 
of several weeks [317].    Stoeva et al. [318] synthesized ~200 nm diameter three-layer 
nanoparticles with a Fe2O3 layer between a SiO2 core and an outer gold shell in a two 
phase process.  Once in aqueous phase, these particles were functionalized with 
oligonucleotides and shown to reversibly bind via DNA hybridization.  Wang et al. [319] 
followed a similar synthesis route to produce iron oxide/gold core/shell nanorods with a 
final length of 250 nm. The synthesis developed by Lyon et al. [64] is entirely aqueous 
and was adapted from an iterative hydroxylamine seeding technique originally suggested 
in [320].  Jeong et al. [321] used the hydroxyl amine seeding protocol to produce a 
magnetic colloid suspension and then attached a functional enzyme to the nanoparticles 
to magnetically decant and recover the enzyme for reuse.  Wang et al. [36] used an 
inverse micelle technique to synthesize magnetic gold particles that could be loaded into 
rat embryonic neural cells for in-vivo MRI imaging.   
Here, we describe a new approach for molecular specific optical imaging in-vitro that 
combines the advantages of molecularly targeted plasmonic nanoparticles and magnetic 
actuation.  This combination is achieved through hybrid nanoparticles with a 
superparamagnetic core surrounded by a gold layer. The nanoparticles were conjugated 
with monoclonal antibodies for molecular recognition.  The hybrid nature of these 
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particles provides new opportunities for optical contrast enhancement.  The addition of 
the gold layer leads to three important advantages: (1) strong optical signal that facilitates 
detection and digital processing; (2) tunable optical resonances; and (3) a convenient 
surface for conjugation of probe molecules [68, 322].  The iron oxide core provides a 
magnetically susceptible component which can be exploited to periodically actuate the 
magnetic particles attached to cells in the field of view and, therefore, allows use of an 
external magnetic field for modulation of the optical signal.  We demonstrate that opto-
magnetic hybrid nanoparticles can be used to increase optical contrast in cancer cell 
imaging.  This report is focused on EGFR – one of the hallmarks of carcinogenesis. 
EGFR has been found to be over-expressed in many types of cancers including lung, 
breast, bladder, cervix, and oral cavity [7]. 
6.3 METHODS 
6.3.1 Iron Oxide/Gold Hybrid Nanoparticles 
Magnetically susceptible plasmonic nanoparticles were synthesized using the method 
described in [64].  Briefly, 9 nm magnetite (Fe3O4) particles were formed via co-
reduction of FeCl2 and FeCl3 in an aqueous NaOH solution.  The Fe3O4 cores were 
oxidized to primarily Fe2O3 by boiling in a 0.01M HNO3 solution.   X-ray diffraction 
measurements (not shown) of the prepared magnetic cores were characteristic for 
maghemite, or γ-Fe2O3.  Subsequently, a ca. 20nm thick gold shell was deposited using 
the hydroxylamine seeding method [320].  This procedure involves sequential additions 
of HAuCl3 in the presence of citrate and hydroxylamine.  It was shown that 
hydroxylamine confines the reduction of Au
3+
 ions to the pre-existing surface of iron 
oxide particles, thereby largely preventing the nucleation of pure gold particles in 
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solution.  The iron seeds and hybrid iron oxide/gold nanoparticles were characterized 
using a Philips EM 208 Transmission Electron Microscope (TEM) equipped with an 
AMT Advantage HR 1MB digital camera detector.  
6.3.2 Antibody Conjugation 
The hybrid nanoparticles were conjugated to anti-EGFR monoclonal antibodies (clone 
29.1.1, Sigma) for molecular specific imaging.  Antibodies were attached to gold 
nanoparticles via a conjugation linker that consists of a short polyethylene glycol (PEG) 
chain terminated at one end by a hydrazide moiety, and at the other end by two thiol 
groups.  First, antibodies at a concentration of 1mg/mL were exposed to 10mM NaIO4 in 
a 40mM HEPES pH 7.4 solution for 30-40 minutes at room temperature, thereby 
oxidizing the hydroxyl moieties on the antibodies’ Fc region to aldehyde groups. The 
formation of the aldehyde groups was colorimetrically confirmed using a standard assay 
with an alkaline Purpald solution (Sigma). Then, excess hydrazide-PEG-thiol linker was 
added to the oxidized antibodies and allowed to react for 20 minutes. The hydrazide 
portion of the PEG linker interacts with aldehyde groups on the antibodies to form a 
stable linkage. In this procedure a potential loss of antibody function is avoided because 
the linker can not interact with the antibody’s target-binding region, which contains no 
glycosylation. The unreacted linker was removed by filtration through a 100,000 MWCO 
filter (Millipore).  After purification, the modified antibodies were mixed with gold 
nanoparticles in 40mM HEPES (pH 7.4) for 20 minutes at room temperature. During this 
step a stable bond is formed between the gold surface and the linker’s thiol groups.  
Afterward, monofunctional PEG-thiol molecules were added to passivate the remaining 
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nanoparticle surface.  Finally, the conjugates were centrifuged at 2800 rcf for 45 minutes 
and resuspended in 1x PBS.  
6.3.3 Cell Culture Model 
EGFR over-expressing A-431 cells [83] were used to demonstrate molecular specific 
imaging with hybrid iron oxide/gold nanoparticles. Cells were cultured in DMEM plus 
10% FBS at 37°C in a 5% CO2 environment.  For labeling experiments, the cells were 
suspended in phenol-free DMEM, mixed with the nanoparticle-antibody conjugates, and 
allowed to react for 20-30 minutes under mild agitation at room temperature.  Typically, 
200-300µL of a cell suspension (~10
5
 cells/mL) was mixed with an equal volume of 
nanoparticles suspended at approximately 10
10
 particles/mL. The labeled cells were 
washed in phenol-free DMEM and resuspended in an isotonic 1% gelatin solution. The 
gelatin provides a viscous environment that is more similar to in vivo conditions than 
pure tissue culture media and also prevents cells from electrostatically adhering to the 
glass coverslip during imaging.  In addition to cells labeled with hybrid nanoparticles we 
included two internal negative controls: unlabeled A-431 cells and cells labeled with 
40nm pure gold nanoparticles.  Because of relatively small optical property differences 
between 40 nm pure gold and 50 nm magnetic gold nanoparticles (only ca. 10 nm 
separation in extinction spectra maxima) we conjugated pure gold particles with 
fluorescently labeled anti-EGFR monoclonal antibodies. Therefore, pure-gold particles 
exhibited a strong fluorescence signal, while the gold/iron oxide particles did not, 
allowing easy discrimination between the two populations of labeled cells.  We used 
AlexaFluor 488 as the fluorescent tag and a standard labeling kit available from 
Molecular Probes to fluorescently label antibodies.  The controls were prepared in the 
 109 
same manner as cells labeled with hybrid nanoparticles and all three cell types were 
mixed together in 1:1:1 ratio.  An aliquot of this mixture was placed on a microscope 
slide for optical measurements.   
6.3.4 Imaging system 
Samples were imaged using a Leica DM 6000 upright microscope in epi-illuminated 
darkfield mode. A 75W Xenon light source was used for illumination.  Images were 
collected through a 20x darkfield/brightfield objective with a 0.5 collection NA, and 
detected using a Q-Imaging Retiga EXi ultra-sensitive 12-bit CCD camera. Time-course 
images of magnetically actuated cells were taken in monochrome mode at approximately 
10 frames per second.  Hyperspectral imaging was used to measure the spectral 
differences between labeled and unlabeled cells. The hyperspectral imaging system 
(PARISS, LightForm, Inc.) incorporates a slit and a prism dispersion configuration.  In 
this scheme, the sample is laterally scanned using a piezoelectric stage, with the slit 
allowing a ~1µm wide portion of the image through the imaging system.  Each line of the 
image is spectrally dispersed via the prism and projected onto a two dimensional CCD 
detector.  The device allows for a spectral range of approximately 350-850nm, and 1 nm 
spectral resolution.  A microscopically clean aluminum mirror was used to collect the 
spectral profile of the light source, which was used to normalize the spectra recorded 
from cells. Fluorescence imaging was performed in epi-mode using a 490nm 
excitation/510nm emission fluorescence filter cube (Chroma).  
6.3.5 Statistical Image Analysis 
For each type of cell (magnetically labeled, pure gold labeled, and unlabeled), as well as 
for each illumination condition (white light and 635nm band-pass illumination) and for 
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Figure 6.1 Experimental setup.  Cells were mounted on a microscope slide and imaged in 
reflected darkfield mode using a Leica DM 6000 upright microscope.  A solenoid 
electromagnet with a cone-shaped ferrite core was attached to a programmable piezoelectric 
translation stage, and placed beneath the sample stage.  Translation stage motion oscillated in 
a sinusoidal fashion with a user-definable amplitude and frequency.  The magnet was 
powered by a power supply and amplifier delivering up to 960 W.  The solenoid and 
motorized translation stage assembly was mechanically isolated from the microscope, which 
sat on a vibration isolation table. 
Power 
Supply 







Solenoid is mechanically isolated from microscope 
Microscope 
Vibration Isolation Table 
Stage 
Sample 
magnetically actuated and un-actuated, 10 cells or more were analyzed.  To calculate 
average signal intensities each cell was manually segmented from the image, the signal 
background subtracted, and the average non-zero pixel intensity values were calculated.  
Then an average signal and standard deviation were determined for each cell type and 
illumination condition. A one-tailed, paired t-test (assuming unequal variances) was 
performed among the three cell populations.  Then, the resulting T statistic then was used 
to calculate a p-value.  Calculations were repeated in both Matlab and Excel for 
confirmation.  
6.3.6 Magnetic actuation  
Figure 6.1 outlines the experimental setup.  A solenoid electromagnet (Ledex 6EC) 














The electromagnet was driven by a power supply and current amplifier, which 
delivered up to 960W to the coil.  The field strength at the tip of the magnet was 0.7 T 
and the field gradient in z-direction from the tip of the core extending 1 mm outward was 
220 T/m.  The electromagnet was attached to a motorized translation stage (Aerotech) 
and driven by a programmable controller that permitted sinusoidal movement with a user 
determined frequency and amplitude.  The motion amplitude was adjusted to 
approximately one full field of view.  Care was taken to ensure that the moving stage was 
mechanically-isolated from the microscope and its vibration isolation table.  Any sample 
movements due to vibrations caused by the moving stage were minimized.  
6.4 RESULTS 
6.4.1 Characterization of Gold/Iron Oxide Multimodal Nanoparticles 
 Figures 6.2A shows transmission electron micrographs of the Fe2O3 core 
nanoparticles before the addition of gold and figure 6.2B reveals the morphology after 
deposition of the gold layer.  The addition of gold results in an approximately 5-fold 
increase in particle diameter. Analysis of TEM images reveals that the average diameter 
of the iron oxide/gold nanoparticles was 50 nm with a standard deviation of 14 nm.  The 
cause for the relatively large size distribution of the resulting nanoparticles is not very 
well understood and it presents a technical challenge that remains to be fully addressed. 
Possible aggregation of the iron oxide core particles before gold deposition might be part 
of the problem.  The process of gold deposition was also monitored using an UV-Vis 
spectrophotometer (BioTek Synergy HT), as shown in figure 6.2C.  Before the addition 
of the gold shell, the extinction properties of the superparamagnetic particles are 
consistent with sub-wavelength sized dielectric spheres.  However, upon addition of the 
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gold layer onto the iron oxide core, the extinction spectrum changes markedly, displaying 
a plasmon resonance peak at 540nm.  We also ran theoretical simulations to model the 
scattering and absorption properties of the gold/iron oxide nanoparticles (figure 6.2D). 
Core-shell composite particle simulations were implemented using custom Matlab/C++ 
codes based on the equations from [323].  Dielectric functions used are based on the 
experimental data from [324], with corrections for the effect of particle size as detailed in 
[325]. Results from these codes have been extensively compared to composite particle 
simulations in the literature.  In order to simulate the effects of a statistical distribution of 
particle sizes, the output from the cross section codes was further integrated using a 
Gauss-Lobatto adaptive quadrature algorithm.  The simulated extinction spectrum is in 
excellent agreement with our measurements (Fig 6.2C).  The simulations showed that the 
peak absorption, extinction, and scattering wavelengths are 534nm, 537nm, and 550nm, 
respectively.  The total scattering from the hybrid nanoparticles represents about 20% of 
the total integrated extinction.   
6.4.2 Darkfield Imaging of Labeled Cells 
Figure 6.3A shows a color dark-field reflectance image of the A-431 cell mixture 
which consists of unlabeled cells (indicated by blue arrows), cells labeled with 50nm 
gold/iron oxide nanoparticles (red arrows) and with 40nm pure gold nanoparticles (green 
arrows).  Magnetic gold and pure gold labeled cells were differentiated from one another 
using a fluorescent tag (AlexaFluor 488, Molecular Probes) that was attached to the 
monoclonal antibodies conjugated with 40nm pure gold nanoparticles but was absent on 
the hybrid nanoparticles (see section 6.3.3).   
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The unlabeled cells appear blue due to the characteristic intrinsic cellular scattering.  
The labeled cells exhibit dim green regions and bright easily identifiable regions with 
different shades of orange.  The green tinge is the color of the isolated nanoparticles and 
corresponds to regions with low density of the contrast agents.  The orange color 
corresponds to the closely spaced assemblies of anti-EGFR gold conjugates which 
interact with EGFR receptors on the cytoplasmic membrane of A-431 cells.  The intensity 
difference between the labeled and unlabeled cells which is achieved under white light 
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Figure 6.2 TEM images of 9nm Fe2O3 nanoparticles before (A) and after (B) deposition of the 
metallic gold layer. Images were collected at 80keV acceleration and 180,000x direct magnification.  
Scale bars are 200nm.  In (C), UV-Vis extinction spectra are shown of a suspension of 9nm Fe2O3 
nanoparticles (blue) and the same suspension after deposition of ca. 20nm gold layer (pink).  Bare 
Fe2O3 particles show typical inverse-power law type extinction properties.  The addition of gold to 
the surface results in the appearance of a characteristic plasmon resonance peak at ca. 540nm. In 
(D), theoretical simulations show the relative contribution of absorption (pink) and scattering (blue) 
to the total extinction (black) of the nanoparticles.  The calculated maximum wavelengths for 
absorption, extinction, and scattering are 534nm, 537nm, and 550nm, respectively and include the 





















Figure 6.3 Darkfield images of a 1:1:1 mixture of A-431 cells labeled with 40nm anti-
EGFR gold nanoparticles (indicated by green arrows), 50nm anti-EGFR gold/iron 
oxide nanoparticles (indicated by red arrows), and unlabeled cells (indicated by blue 
arrows) obtained using: (A) white light illumination; and (B) a 630±15nm bandpass 
filter.  Images were acquired with a 20x darkfield/brightfield objective with a 0.5 
collection NA.  (C) Scattering spectra of cells labeled with 50 nm hybrid nanoparticles 
(red line), 40nm pure gold nanoparticles (green line) and of unlabeled cells (blue line).  
A fluorescent tag (AlexaFluor 488, Molecular Probes) was attached to the pure gold-
antibody conjugates in order to differentiate between the two types of labeled cells. 
the illumination path (figure 6.3B).  This is possible because the endogenous scattering of 
cells (Fig. 6.3C, blue line) is significantly reduced in the red optical region [326].  In 
addition, cells labeled with 50 nm hybrid particles display a prominent scattering peak in 
the red region at approximately 690 nm (Fig. 6.3C, red line). Similar behavior is observed 








































6.4.3 Magnetic Actuation of Cells 
Despite the unique contrast-enhancing mechanism afforded by the plasmon resonance 
coupling of gold nanoparticles, unlabeled cells can still be discerned in images obtained 
using both white light and red band-pass illumination (figures 6.3 A and B).  To further 
increase contrast between labeled and unlabeled cells, we explored the magnetic 
component of the hybrid contrast agents.  The experimental set-up for magnetic actuation 
of labeled cells (figure 6.2) is based on the following principles. The force exerted on the 
nanoparticles is proportional to the gradient of the square of the magnetic field magnitude 
[312], and acts in the direction of increasing gradient; thus the iron oxide nanoparticles 
tend to move towards the ferrite tip in the solenoid when current is applied.  By 
oscillating the tip of the solenoid in a sinusoidal fashion in the horizontal or x-direction, 
the changing direction of force exerted on the nanoparticle-labeled cells causes an 
oscillating displacement in the cells’ position. The magnitude of the oscillation was 
approximately 1 field of view, or 500 microns.  Magnetically induced movement of cells 
labeled with iron-oxide/gold nanoparticles is shown in figure 6.4.  Images were collected 
and replayed at 10 frames per second. As can be seen, the horizontal translation of the 
solenoid tip causes horizontal fluctuations in the cell position due to interaction between 
the electromagnet and the magnetic nanoparticles which are attached to EGFR molecules 
on cellular surface.  In addition, however, there also exists a y-component of the 
magnetic force due to the fact that the ferrite tip is not positioned directly beneath the cell 





Cells that are not perfectly aligned in z-direction with the solenoid tip experience a 
non-oscillatory component in the y-direction. It is also important to note that the solenoid 
exerts the bulk of its force in the z-direction, parallel to the microscope’s optical axis.  
While cell translation is confined in this direction due to the presence of the microscope 
slide and coverslip, it may produce an overall torque on cells that have an uneven angular 
distribution on particles on their surfaces.  This will result in a torque, causing signal 
fluctuations at the same frequency as the solenoid oscillation, and thus will contribute to 
the overall magnetic actuation effect.  Any significant signal fluctuations at the 
modulation frequency of the solenoid are absent in the case of unlabeled cells and cells 
labeled with pure gold nanoparticles or background.   
6.4.4 Fourier Analysis of Cell Actuation Images 
To analyze the specific frequency components of the acquired signals, a fast Fourier 
transform (FFT) was performed at each pixel of the acquired images in the time domain 
Figure 6.4. Two images, taken approximately 2 seconds apart, showing the magnetically 
induced movement of gold-iron oxide nanoparticle labeled A-431 cells captured under 20x 
magnification, and using a 635/15nm bandpass illumination filter.  Note that there is no 
relative movement of unlabeled cells (which appear dim) and pure-gold labeled cells 
(identified by the overlaid green fluorescence signal).  The magnetically labeled cell (bright 
with no overlaid green fluorescence) clearly responds to the oscillating magnetic by moving 
relative to the other cells, as indicated by the different sized arrows in both images.  Scale bar 




and power spectra were calculated at each pixel position.  Oscillation frequencies of the 
magnet and the total number of acquired images were chosen to avoid any aliasing 
effects.  The precise sampling frequency was calculated via a time stamp generated in 
each image file that is accurate to 0.001 seconds. Figures 6.5(A) and (B) show 
monochrome darkfield images of a mixture of cells that are labeled with gold/iron oxide 
particles, with pure gold particles, as well as unlabeled cells, collected under 635/15nm 
bandpass illumination.  The samples were subjected to a magnetic field oscillation with 
frequencies of 0.9Hz (A) and 1.9Hz (B).  After data acquisition, images were analyzed in 
Matlab. Figures 6.5(C) and (D) show examples of frequency power spectra from 
magnetic gold labeled (red line), pure gold labeled (green line), and unlabeled cells (blue 
line), for magnetic oscillations with frequencies 0.9 and 1.9 Hz, respectively.   Frequency 
spectra of signals recorded from cells labeled with the magnetic/gold nanoparticles 
display a prominent peak at the corresponding stage oscillation frequency.  Such a peak is 
much less apparent in the case of unlabeled cells or cells labeled with pure gold 
nanoparticles, indicating that these cells are not displaced by the spatiotemporally 
oscillating magnetic field.  These results also suggest that secondary effects such as 
localized temperature-induced convection currents within the gelatin matrix are minimal.  
Time-varying signal intensities are predominant in only those regions of interest which 
contain the magnetically labeled cells.  To isolate magnetically modulated components in 
the acquired images, we used a Hanning window method implemented in Fourier space 
[327].  First, image series were subjected to the appropriate window function and, then, to 
an inverse Fourier transform at each pixel in the time-dimension. Finally, images were 
rescaled via a simple linear multiplier to maximize the pixel intensity range.  It is 
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important to note that images were not subjected to any thresholding procedure (whereby 































Figure 6.5 1:1:1 mixture of A-431 cells labeled with 40nm anti-EGFR gold nanoparticles 
(green arrows), 50nm anti-EGFR gold/iron oxide nanoparticles (red arrows), and 
unlabeled cells (blue arrows) that were magnetically actuated at 0.9Hz (A) and 1.9Hz (B) 
before application of a digital frequency filter. The images were obtained using a 635/15nm 
bandpass filter. Sections (C) and (D) show power spectra that are taken from the time-
domain Fourier transform in the region containing a cell labeled with 50nm gold/iron 
oxide particles (red), 40nm pure gold particles (green) and an unlabeled cell (blue).  Note 
the prominent peaks in the magnetically-labeled cells’ frequency spectra that correspond 
to the translation stage oscillation frequencies of 0.9Hz (C) and 1.9Hz (D).  Sections (E) and 
(F) show the same fields of view as sections (A) and (B), respectively, after digital filtering 
at 0.9Hz (E) and 1.9Hz (F) uses the Hanning function implementation.  Only magnetically 
labeled cells are visible. 
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Figure 6.5(E) and (F) show the same fields of view as figure 6.5 (A) and (B), 
respectively, after digital filtering at the appropriate frequencies (0.9Hz and 1.9Hz) and 
rescaling.  As a result of this treatment, signals associated with unlabeled cells, and pure 
gold-labeled cells are no longer apparent in images filtered at both 0.9Hz (figure 65 E) 
and 1.9Hz (figure 6.5 F). 
6.4.5 Quantitation of Contrast Enhancement 
The implementation of frequency domain filtering techniques results in greater 
contrast enhancement as compared to purely optical methods.  To demonstrate this 
contrast enhancement quantitatively, pixel intensity profiles were drawn across images of 
magnetic gold-labeled (red line), pure-gold labeled (green line) and unlabeled cells (blue 
line) which were obtained under different illumination conditions and with the 
combination of the 635 nm illumination and frequency domain filtering (figure 6.6A).  
We also calculated the average signal intensities for each of the three cell populations in 
images that were acquired under four different acquisition and processing conditions: (1) 
white light illumination, (2) 635/15nm bandpass illumination, (3) white light illumination 
followed by magnetic actuation and frequency domain filtering, and (4) 635/15nm 
bandpass illumination followed by magnetic actuation and frequency domain filtering.  
Results of this analysis are shown in figures 6B and C.  Under white light illumination, 
signal from cells labeled with magnetic and non-magnetic gold particles are statistically 
identical and the unlabeled cells are on average 2.5 times dimmer.  Addition of the 
635/15nm bandpass filter increases the intensity difference between labeled and 
unlabeled cells to approximately 4 (figure 6B).  Interestingly, implementation of 































































































Figure 6.6 In (A), pixel intensity profiles are shown for the three cell types: 50nm gold/iron oxide 
labeled (red line), 40nm pure gold labeled (green line), and unlabeled (blue line).  Profiles are drawn 
for the same three cells captured using white light illumination, 635/15nm bandpass illumination, as 
well as bandpass plus magnetic actuation and digital frequency filtering.  In (B) and (C), the relative 
average pixel intensity from n>10 cells in each cell population and illumination/acquisition condition 
is compared.  Asterisks and brackets in (B) and (C) indicate a statistical significant difference of the 
average signal values with p<10
-4
. 
independent of which illumination condition is used, as shown in figure 6C.  The average 
signal intensity ratio between gold/iron oxide and pure gold labeled cells increases from 
approximately 1 in the case of no magnetic actuation to about 3 with the magnetic 
actuation.  At the same time, the intensity ratio between gold/iron oxide labeled cells and 
unlabeled cells increases from approximately 2.5-3 to ca. 10 under both illumination 
conditions.  Asterisks in figure 6B and C indicate a statistically significant difference in 
the average signal values with p<10
-4
 between the three cell types within each acquisition 
condition.   These results demonstrate that frequency domain filtering is very sensitive to 
the magnetically controlled movement of cells.  
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6.5 DISCUSSION 
The use of nanoparticle technology affords a flexible platform for interrogation of 
biological systems at the molecular level.  Remaining barriers exist towards realizing a 
robust and generalized tool set that could potentially be used in molecular biology and 
healthcare settings.  While issues such as biocompatibility and toxicity are of paramount 
importance, the ability of nanoparticle-based exogenous contrast agents to generate 
strong easily detectable signals which are above the endogenous background requires 
further investigation.  For example, in fluorescence imaging techniques, background 
autofluorescence can present a difficult barrier to overcome [180].  Further, 
photobleaching can drastically reduce the ability to monitor longer-term molecular 
processes or response to therapies.  
High background scattering from various tissue architecture can make the isolation of 
molecular specific signals difficult in reflected/scattered light imaging modalities such as 
reflectance confocal microscopy and OCT.  Therefore, the development of multi-faceted 
approaches is essential to improve the sensitivity of molecular imaging techniques.  Here 
we demonstrate that the combination of plasmon resonance scattering inherent in gold 
nanoparticles with magnetic actuation results in ca. 10 fold intensity ratio between the 
labeled and unlabeled cells under white light illumination; this is almost a four times 
increase over the same ratio for the pure gold nanoparticles.  Also, under optimized 
bandpass illumination the magnetically actuated cells appear 3 times brighter than cells 
labeled with pure gold nanoparticles after application of the digital filtering (figure 6.6C). 
We demonstrate this new approach in A-431 skin cancer cells.  These cells are 
keratinocytes which produce massive amounts of cytokeratin and, therefore, strongly 
scatter visible light.  We chose this less than deal biological model because of the very 
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high endogenous scattering in order to evaluate the new approach in the presence of a 
high background signal.  Our results indicate that magnetic actuation of these hybrid 
nanoparticles may be used to drastically reduce signals from non-magnetically 
susceptible background sources.  This ability may be vital in potential future in-vivo 
molecular imaging applications, where it is crucial to isolate the distribution of molecules 
of interest from a dense, highly complex background.  Interestingly we note that our 
results also showed that hybrid magnetic gold nanoparticles can be easily distinguished 
from pure gold nanoparticles using magnetic actuation.  This opens the possibility of a 
multiplexing approach that uses combinations of magnetic and non-magnetic gold 
particles in molecularly labeling distinct sub-populations of cells.  Further, the analysis 
algorithm can potentially be incorporated such that Fourier-based filtering can be 
accomplished in near-real time. There are a number of other potential applications 
whereby magnetically actuated hybrid particles may be applied.  The ability to both 
magnetically manipulate and monitor cells on the nano-scale with molecular specificity is 
an exciting direction for further research. For example, pure magnetic nanoparticles 
(MNPs) were used to probe the mechanical properties of proteins both separately and 
inside cells [328-330].  However, these studies are still limited by micron size of these 
particles and their relatively low brightness. The magnetically actuated plasmonic 
nanoparticles can drastically improve the spatial resolution of these studies and signal-to-
noise ratio in monitoring of a mechanical response. Further, the field of molecular-
specific mechanotransduction may greatly benefit from the ability to both mechanically 
manipulate cells using an external magnetic field and monitor cellular response in real 
time with a single agent.   
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Conclusions and Future Directions 
7.1 CONCLUSIONS 
As was shown in Chapter 3, cells labeled with anti-EGFR gold nanoparticles display 
a plasmon resonance peak that can be shifted over 100nm from that seen in solution, into 
the red and near infrared spectral regions.  This, in combination with coherent back 
scattering effects that non-linearly increase the overall optical cross section of the system, 
produce a bright characteristic scattering signal from EGFR over-expressing cells.  The 
red shifting and coherent back scattering effects were shown independently via 
hyperspectral imaging, and bi-functional fluorescence/reflectance contrast agents, 
respectively.  Red shifting of the plasmon resonance is an active area of theoretical 
investigation.  From a simplified point of view, it can be seen that a particle pair whose 
longitudinal axis is parallel to the electric field polarization experiences a relaxation in 
the energy required to initiate the conduction band electron oscillation – thus producing a 
red shift in their collective resonance.  It has been shown that this dipole-dipole coupling 
depends on the cube of the interparticle distance [197] .  Subsequent examination of 
labeled cells in electron microscopy images shows that these inter-particle distances are 
well within the range where plasmon coupling is prominent, deemed to be less than three 
times the diameter [197].   
Further investigations in Chapter 4 indicate that the degree of plasmon coupling is 
intimately intertwined with the trafficking events that are a part of the EGFR life cycle 
within the cell.  Cells labeled at low temperatures, where endocytosis is inhibited, show 
far less red-shifting than those labeled at higher temperatures. Further electron 
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microscopy investigations confirm that the these spectral changes are a result of the 
increase in inter-particle spacing, as well as a shift into three dimensional organization 
due to endocytosis.  These studies showed conclusively that metal nanoparticles are 
sensitive to the nanoscale arrangement of EGFR molecules.  However, a unified view 
that  relates the degree of plasmon coupling to specific molecular events such as receptor 
dimerization [331], clustering in clathrin coated pits [134], as well as endosomal fusion 
and degradation is still an ongoing process [137]. 
When this technology is applied to more complex biological models, a system of 
delivery becomes a major factor of consideration.  Adjuvants such as DMSO may play a 
critical role in aiding the delivery of nanoparticles topically, and experimentation with 
various complex pre-clinical models bears this out, as shown in Chapter 5.  Large 
differences in signal are seen between normal and abnormal cervical biopsies, and this 
contrast monotonically increases with the severity of the neoplastic growth.  Critical 
questions remain, however, as to the eventual adoption of such a strategy into clinical 
use.  Questions remain as to whether effects such disease-modulated increases in tissue 
permeability translate into an additional reliable means to target abnormal cells in-vivo, 
or whether it will result in highly variable and unpredictable results from patient to 
patient.  Certainly, a more thorough investigation is needed in this regard.  In addition, 
exploring the use of metal nanoparticles in cases of advanced metastatic disease has 
certainly been encouraged from the initial results seen in Chapter 5.  However, there 
remains much further work in identifying strategies and limitations for sentinel lymph 
node detection. 
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As was shown in chapter 5, as well, was the tendency of some tissues to exhibit less 
than ideal morphology and organization.  This might include high keratin expression 
which seems to block delivery of nanoparticles as well as light, as well as other 
endogenous sources of signal such as immuno-induced fibrotic encapsulation.  These few 
examples demonstrate the nature of biological tissue as being highly complex, 
heterogeneous, and often difficult environments in which to image.  As such, a 
multifaceted approach may be necessary to extract the requisite amount of information 
from a sample.  Chapter 6 outlines an example of such an approach, whereby molecular 
specific signal is modulated by means of an oscillating magnetic field and a 
plasmonic/magnetically susceptible nanoparticle.  This provides an “encoding” 
mechanism that allows extraction of the signal of interest from a noisy or large 
background.   
The overriding aim of the studies presented in this dissertation is to establish 
paradigms for future work to continue evaluating the use of immuno-targeted gold 
nanoparticles for optical molecular imaging.   In particular, this work demonstrates the 
importance of the concept of plasmon coupling as a valuable and unique mechanism for 
optical molecular imaging.  As evidenced by the number of publications that have 
appeared in the last 4-6 years, optical molecular imaging is fast becoming a major field in 
biomedicine [60, 144, 171, 245, 332-334].  From these studies and others, plasmonics 
certainly has a vital role to play in these efforts [264, 280, 335, 336].  Their strong signal 
due to large electromagnetic enhancement, resistance to photobleaching, and 
straightforward conjugation to targeting moieties makes these types of nanomaterials 
very attractive for biological interfacing devices.  Surface plasmon coupling, while 
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recognized as a physical phenomenon for some time [74, 191], has not until recently been 
shown to be useful in a biological sensing arena [71], albeit so far in the simplest form of 
a single pair of interacting particles isolated in-vitro for detection of DNA behavior.  
While exciting, we believe the studies described in this dissertation serve to vastly 
expand the feasibility of this concept to reliably sense protein assemblies in-situ, and in-
vivo, thereby making this technology much more widely applicable and useful.    
 7.2 FUTURE DIRECTIONS 
The future opportunities for further development of this technology are wide ranging., 
as evidenced by the number of new avenues of research that are being put forth.  As was 
briefly mentioned in the previous section, there are two main areas which certainly 
deserve further examination.  First is development of a better understanding of the 
biomolecular trafficking and activation events incorporated into the EGFR life cycle, and 
how these affect plasmon coupling.  Or, conversely, to what extent can plasmon coupling 
be used to image and understand the nanoscale relationship of molecules such as EGFR 
in and on the cell?  The second main area would be to further explore and develop 
delivery mechanisms for eventual adoption of plasmonic nanoparticles into clinical 
practice.  While data have been encouraging, the effects of cancer on tissue permeability 
and biomarker access are still largely unknown.  There certainly may be alternative 
delivery strategies and techniques that may increase the overall clinical applicability and 
performance, such as systemic delivery, or more bio-specific delivery strategies such as 
viral or other pathogenically derived strategies.   
In the longer term, there are potential expansions of the current state of the art that 
will make plasmonics even more attractive from both a clinical and biological 
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perspective.  Firstly, the use of hybrid nanoparticles was demonstrated in Chapter 6.  
Similar particles may be used as dual imaging contrast agents in both MRI and optical 
measurements.  This has the distinct advantage of exploiting the large imaging volumes 
inherent in MRI, and the high resolving power using optics, and again underscores the 
need for multifaceted approaches in molecular imaging.  Finally, plasmonic devices can 
act as both passive reporters, as well active agents of intervention in cells.  Synthesizing 
optical diagnostics and photothermal treatment of diseased tissue, or magnetically 
induced mechanotransduction may open up nearly limitless applications.  In short, it is 
not likely that potential new applications of plasmonics in biology will be exhausted in 









































































































%PARISS hyperspectral data cube builder  
%by Jesse Aaron 
%Last Update Feb. 2007 
%__________________________________________________________________________ 
% 
%This program will import PARISS hyperspectral data to a .mat file.  The 
%data must be fist converted from .prs to .txt format using Jeremy's LabView  
%conversion utility before running this m-file.  This program prompts user 
%for a Sample data directory and a Normalization data directory (they must 
%be different).  If the data does not require normalization, press cancel 
%when prompted for the normalization image.   
% 
%The program outputs are p (the hyperspectral data cube), lam (the 
%wavelength vector), and date (the date/time the data was acquired). 
  
clear all; close all; home 
datapath = uigetdir('C:','Select Directory Containing Sample Data .txt Files'); 
whitepath = uigetdir(datapath,'Select Directory Containing Mirror Spectra .txt File. 
Press Cancel If None'); 
stdpath = uigetdir(datapath,'Select Directory Containing Mirror Standard .txt File.  
Press Cancel If None'); 
filelist = dir(fullfile(datapath,'*.txt')); 
  
%Import & normalize using a "perfect" substrate (such as labsphere or Al mirror) 
if (whitepath(1) ~= 0) & (stdpath(1) == 0) 
    white = dir(fullfile(whitepath,'*.txt')); 
    numw = textread(fullfile(whitepath,white.name),'%f','headerlines',1); 
    numw = reshape(numw,241,1,length(numw)/241); 
    pw = numw(2:size(numw,1),1,:); 
    clear numw 
%Import and normalize using a "standard" substrate (such as gold mirror) 
elseif (whitepath(1) ~= 0) & (stdpath(1) ~= 0) 
    white = dir(fullfile(whitepath,'*.txt')); 
    numw = textread(fullfile(whitepath,white.name),'%f','headerlines',1); 
    numw = reshape(numw,241,1,length(numw)/241); 
    stand = dir(fullfile(stdpath,'*.txt')); 
    nums = textread(fullfile(stdpath,stand.name),'%f','headerlines',1); 
    nums = reshape(nums,241,1,length(nums)/241); 
    pw = numw(2:size(numw,1),1,:)./nums(2:size(nums,1),1,:); 
    clear numw nums 
%Import without any normalization (such as fluorescence or raw spectra) 
elseif (whitepath(1) == 0) & (stdpath(1) == 0) 
    pw = 1; 
end 
  
%Copy and read .txt files (must be in their own directory) 
for a = 1:length(filelist) 
    num = textread(fullfile(datapath,filelist(a).name),'%f','headerlines',1); 
    num = reshape(num,241,1,length(num)/241); 
    rawdata = num(2:size(num,1),1,:); 
    warning('off'); 
    normdata = rawdata./pw; 
    clear rawdata 
    p(:,a,:) = normdata; 
    clear normdata 
    progress = round(a/length(filelist)*1000)/10; 
    home 
    disp(strcat('progress:',num2str(progress),'%')); 
end 
  
%Pre-processing of data 
p = p(:,:,46:446); %only consider data from 400-800nm (outside this range is too noisy) 
p(isnan(p) == 1) = 0; p(isinf(p) == 1) = 0; %get rid of any divide-by-zero errors 
lam = num(1,1,:); lam = reshape(lam,1,size(lam,3)); %construct wavelength vector 
lam = lam(46:446); %make wavelength vector match cropped data (400-800nm) 
date = filelist(a).date; %provide acquisition time 
clear num pw filelist %clean up memory 










%Wavelength intensity plot 
%By Jesse Aaron 
%Last update Oct. 2006 
%__________________________________________________________________________ 
% 
%[IMG] = INTPLOT(P,LAM,LAMBDA,CLIM) 
% 
%This function plots the intensity of a hyperspectral image at given 
%wavelength. 
% 
%The inputs are: 
% 
%p: The hyperspectral data as generated by hyperspec.m 
% 
%lam:  The wavelength vector as generated by hyperspec.m 
% 
%lambda: The approximate wavelength or wavelength range at which to view 
%        the intensity.  In the case of a range of wavelengths, input the first and 
%        last wavelengths to consider in vector form.  The image will show the integrated  
%        signal over this range.   
% 
%clim: A 2-element vector that gives the min and max values to display in 
%      the image.  If clim is set to zero, the limits will automatically  
%      be set to the min and max of the image. 
% 
%The output is: 
% 
%A image that contains the intensity image.  This can be saved as a 
%.fig file or exported as a .tif file. 
  
function [img] = intplot(p,lam,lambda,clim) 
%find nearest wavelength point to input 
mindiff = abs(lam - min(lambda)); 
maxdiff = abs(lam - max(lambda)); 
  
%single wavelength case 
if  mindiff(1) == maxdiff(1) 
    diff = mindiff; 
    index = find(diff == min(diff)); 
    img = p(:,:,index); 
     
%wavelength range case 
else 
    index1 = find(mindiff == min(mindiff)); 
    index2 = find(maxdiff == min(maxdiff)); 
    pimg1 = p(:,:,min(index1,index2):max(index1,index2)); 
    img = sum(pimg1,3); 
end 
  
%default setting if clim = 0 
if clim == 0 










if mindiff(1) == maxdiff(1) 
    ttl = ['Intensity at ',num2str(round(lam(index))),' nm']; 
else 
    ttl = ['Integrated intensity from ' num2str(round(lam(index1))) ' to ' 






%Spectra plot for PARISS(R) 
%By Jesse Aaron 
%Last update Oct. 2006 
%__________________________________________________________________________ 
% 
%[IMG,INT,LAM] = SPECTRAPLOT(P,LAM,COORDX,COORDY,SMOOTHING) 
% 
%This function plots the spectra from within a given ROI in a hyperspectral 
%image.  The inputs are: 
% 
%p:  The hyperspectra data as generated by hyperspec.m 
% 
%lam: The wavelength vector as generated by hyperspec.m 
% 
%coordx:  The x-coordinate of the ROI.  It can be a single value, or a range  
%         covering more than one pixel in the x (horizontal) direction.  If 
%         set to zero, it will allow user to select a ROI using a mouse. 
% 
%coordy:  The y-coordinate of the ROI. It can be a single value, or a range  
%         covering more than one pixel in they y (vertical) direction. If 
%         set to zero, it will allow user to select a ROI using a mouse. 
% 
%smoothing:  Set to zero for no smoothing, set to 1 for moving average or 
%            "boxcar" smoothing.  Default window size is 5nm. 
% 
%The outputs are: 
% 
%A matlab figure showing the Intensity vs. wavlength plot. 
% 
%A .xls file containing the data for later plotting.  Int is the intensity, 
%lam is the wavelength vector. 
% 
function [img,Int,lam] = spectraplot(p,lam,coordx,coordy,smoothing); 
p2 = reshape(p(:,:,151),size(p,1),size(p,2)); %show intensity image at 550nm 
if (coordx == 0) & (coordy == 0) 
    imagesc(p2,[0 2]); hold on; axis image; colorbar 
    rect = getrect(gcf); x = round([rect(1) rect(1)+rect(3)]); y = round([rect(2) 
rect(2)+rect(4)]); 
else 
    x = [min(coordx) max(coordx)]; y = [min(coordy) max(coordy)]; 
end 
  
spx = p(y(1):y(2),x(1):x(2),:); 
spx_ave = mean(mean(spx,1),2); 
spec = reshape(spx_ave,1,size(p,3)); 
  
if smoothing == 1 




figure; plot(lam,spec); hold on 
xlabel('Wavelength (nm)'); ylabel('Intensity (au)'); 
xlim([400 800]); ylim('auto'); 
hold off 
  
data = [lam' spec']; 
xlswrite('spectraplot.xls',data); 
[filename path] = uiputfile('.xls','Save Spectral Data in .xls File'); 
Int = spec;  
if filename ~= 0 




if (path ~= 0) & (strcmp(cd,path) ~= 1) 






function [maxtab, mintab]=peakdet(v, delta) 
%PEAKDET Detect peaks in a vector 
%        [MAXTAB, MINTAB] = PEAKDET(V, DELTA) finds the local 
%        maxima and minima ("peaks") in the vector V. 
%        A point is considered a maximum peak if it has the maximal 
%        value, and was preceded (to the left) by a value lower by 
%        DELTA. MAXTAB and MINTAB consists of two columns. Column 1 
%        contains indices in V, and column 2 the found values. 
  
% Eli Billauer, 3.4.05 (Explicitly not copyrighted). 
% This function is released to the public domain; Any use is allowed. 
  
maxtab = []; 
mintab = []; 
  
v = v(:); % Just in case this wasn't a proper vector 
  
if (length(delta(:)))>1 
  error('Input argument DELTA must be a scalar'); 
end 
  
if delta <= 0 
  error('Input argument DELTA must be positive'); 
end 
  
mn = Inf; mx = -Inf; 
mnpos = NaN; mxpos = NaN; 
  
lookformax = 1; 
  
for i=1:length(v) 
  this = v(i); 
  if this > mx, mx = this; mxpos = i; end 
  if this < mn, mn = this; mnpos = i; end 
   
  if lookformax 
    if this < mx-delta 
      maxtab = [maxtab ; mxpos mx]; 
      mn = this; mnpos = i; 
      lookformax = 0; 
    end   
  else 
    if this > mn+delta 
      mintab = [mintab ; mnpos mn]; 
      mx = this; mxpos = i; 
      lookformax = 1; 
    end 
  end 
end 
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%Maximum wavelength plot 
%By Jesse Aaron 
%Last update Feb. 2007 
%__________________________________________________________________________ 
% 
%[IMG2] = MAXLAM(P,LAM,THRESHL,THRESHU,CLIM) 
% 
%This function finds the highest peak (local maximum) in each spectrum (within a range of 
wavelengths) 
%and plots an image of the peak wavelengths at each pixel, represented by a RGB color 
map. 
% 
%The inputs are: 
% 
%p:  The hyperspectra data cube as generated by hyperspec.m 
% 
%lam:  The wavelength vector as generated by hyperspec.m 
% 
%threshl:  The lower signal threshold that will be considered. 
% 
%threshu:  The upper signal threshold that will be considered. 
% 
%clim:  The wavelength range over which to look for peaks. 
% 
%delta:  The sensitivity of the peak detection (0.1 is a good value). 
% 
%The output is: 
% 
%An image that contains the maximum wavelength image.  This can be saved as a 
%.fig file or exported as a .tif file. 
  
function [img2] = maxlam(p,lam,threshl,threshu,clim,delta); 
  
diff1 = abs(lam - min(clim)); 
diff2 = abs(lam - max(clim)); 
index1 = find(diff1 == min(diff1)); 
index2 = find(diff2 == min(diff2)); 
  
%threshold image 
maxpthresh = p(:,:,151).*(p(:,:,151) < threshu).*(p(:,:,151) > threshl); 
  
%find pixel positions of non-zero results 
[x1 y1] = find(maxpthresh ~= 0); 
  
%skeleton image 
img2 = zeros(size(p,1),size(p,2)); 
  
for a = 1:length(x1) 
   spec = reshape(p(x1(a),y1(a),:),1,length(lam)); %1D spectrum 
   spec = moving_average(spec,5); 
   [maxtab] = peakdet(spec,delta); 
   peaktab = [lam(maxtab(:,1))' maxtab(:,2)]; 
   inrange = find(peaktab(:,1) > lam(index1) & peaktab(:,1) < lam(index2)); 
   peaktab = peaktab(inrange,:); 
   if isempty(inrange) == 1 
       peak = lam(1); 
   else 
       highest = find(peaktab(:,1) == max(peaktab(:,1))); 
       peak = peaktab(highest,1); 
   end 
   img2(x1(a),y1(a)) = peak; 
end 
  
cmap = colormap; 
cmap(1,:) = [0 0 0]; 
  















%Maximum wavelength histogram maker 
%By Jesse Aaron 
%Last update Feb. 2007 
%__________________________________________________________________________ 
% 
%[N,X] = MAXHIST(P,LAM,THRESH,CLIM) 
% 
%This function generates a histogram of wavelengths corresponding to 
%maximum signal intensities in an image.  The histogram can be generated 
%for a user-selectable ROI in the image using the mouse. 
% 
%The inputs are: 
% 
%p:  The hyperspectral data cube as generated by hyperspec.m 
% 
%lam:  The wavelength vector as generated by hyperspec.m 
% 
%threshl:  Lower signal threshold to consider 
% 
% 
%clim:  Wavelength range to plot in the histogram.  If clim is set to zero, 
%       the the limits will automatically be set to the min and max of the image. 
% 
%delta:  The sensitivity of the peak detection. (0.1 is a good value) 
% 
%bin:  The histogram bin size (in nm). 
% 
%The outputs are: 
% 
%A .fig file that shows the frequency histogram of the maximum intensity 
%wavelengths. 
% 
%A .xls file which can be saved containing the wavelength vs. frequency 
%data. N is the frequencies, x is the bin center values. 
  
function [N,x,stats] = maxhist(p,lam,threshl,threshu,clim,delta,bin); 
  
img2 = maxlam(p,lam,threshl,threshu,clim,delta); 
  
rect = round(getrect(gcf)); 
x = [rect(1) rect(1)+rect(3)]; y = [rect(2) rect(2)+rect(4)]; 
roi = img2(y(1):y(2),x(1):x(2)); 
list = reshape(roi,size(roi,1)*size(roi,2),1); 
zeroind = find(list == 0); list(zeroind) = [];%get rid of zeros 
climind = find(list < min(clim) | list > max(clim));%get rid of peaks outside range 
list(climind) = []; 
[N,x] = hist(list,[min(clim):bin:max(clim)]); 
ave = mean(list); 
medianval = mode(list); 
stdev = std(list); 
stats = {'Average' ave; 'Sigma' stdev; 'Median' medianval}; 
  
figure; hist(list,[min(clim):bin:max(clim)]); hold on 
title(['Mean = ' num2str(round(ave)) '  Stdev = ' num2str(round(stdev*100)/100) ' Median 
= ' num2str(round(medianval))]); 
xlabel('Peak Wavelength (nm)'); ylabel('Frequency'); 
hold off; 
data = [N' x']; 
xlswrite('histogram.xls',stats); 
xlswrite('histogram.xls',data,1,'A5'); 
[filename pathname] = uiputfile('*.xls','Save Histogram Data'); 
if filename ~= 0 




if (pathname ~= 0) & (strcmp(cd,pathname) ~= 1) 
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